Conditions: Degenerative Disc Disease Intervertebral Disc Disease Low Back Pain
Keywords: Degenerative Disc Disease, Intervertebral Disc Disease Low Back Pain Nucleus pulposus Stem cell Cellular therapy Regenerative therapy Mesenchymal stem cells Bone marrow Musculoskeletal Diseases Mesenchymal Stromal Cells (allogenic)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 24
Healthy volunteers: no

Brief summary:
In this study we want to evaluate the clinical use of allogenic mesenchymal stem cells (MSC), obtained from bone marrow of healthy donors, for treatment of Degenerative Disc Disease (DDD). The trial is based in previous results with autologous MSC (Orozco et al., Transplantation 92: 822-828; 2011). Here we propose a phase I-II trial, prospective, randomized, blinded, and controlled for the treatment DDD using MSV, a Good Manufacturing Practice (GMP)-compliant expanded bone marrow MSC (MSV, Investigational medicinal product Num. 10-134). The assay consists of two arms with 12 patients each one. Patients in the experimental arm will be given a single intra-discal transplantation of MSV (25 millions in 2 ml). Control patients will be infiltrated in the paravertebral muscles close to the lesion with 2 ml of 1% mepivacain. We shall follow the evolution of pain, disability and quality of life as well as disc fluid content by Magnetic Resonance Imaging (T2-calibrated).

Detailed description:

Arms:
arm 1: Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline arm 2: Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine

Interventions: intervention 1: Allogenic Mesenchymal Stromal Cells intervention 2: Mepivacaine
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document:
Prot_SAP_ICF_000.pdf: 
                                         Disc_allo_MSV protocol. v.1.6 1                             1 
 
Disc_allo_MSV protocol. v.1.6 1  
 
 
NCT01860417    
CLINICAL TRIAL PROTOCOL: 
Treatment of lumbar degenerative disc disease with allogeneic mesenchymal cells 
(MSV *). * MSV: "Ex Vivo" expanded bone marrow stromal mesenchymal cells with 
GMP procedure of the Institute of Molecular Biology and Genetics of Valladolid 
Version: October 3, 2012 
(Treatment of degenerative disc disease with allogenic mesenchymal cells  MSV) 
CLINICAL TRIAL PROTOCOL 
Eudra-CT: 2012-004444-30 
Code: Disc_allo_MSV 
Title: Treatment of lumbar degenerative disc disease with allogeneic mesenchymal 
cells (MSV). * MSV: "Ex Vivo" expanded bone marrow stromal mesenchymal cells with 
GMP procedure of the Institute of Molecular Biology and Genetics of Valladolid 
Development phase: Phase I – II 
Version: 1.6, of October 3, 2012 
 
Sponsor: Citospin, Scientific Park of the University of Valladolid R + D Building, Paseo 
de Belén, 11. Campus Miguel Delibes, 47011 Valladolid. NIF. B-47673538 
Confidential Property: The information included in this protocol is confidential. It is 
directed and available only to researchers, health authorities and responsible members 
of the Ethics Committee for Clinical Research. No part of it may be reproduced, 
transmitted, revealed or used in any way without the written authorization of the 
promoter of the study. These restrictions will apply to all signatories of this Protocol. 
 
 
LIST OF ABBREVIATIONS 
AA Adverse event 
AAG Serious adverse event 
AEMPS Spanish Agency for Medicines and Health Products 
GCP Good Clinical Practice (GCP) 
GLP Good Laboratory Practice (GLP) 
CEIC Ethical Committee for Clinical Research 
CMN Mononuclear cells 
CRD Data Collection Notebook 
ECG Electrocardiogram 
FTH Teófilo Hernando Foundation 
DDL Lumbar Degenerative Discopathy 
GMP Good Manufacturing Practice or Good Manufacturing Practice (NCF) 
HCUVa Hospital Clínico Universitario de Valladolid 
IBGM Institute of Molecular Genetic Biology, Uva 
ICH International Conference on Harmonization 
LSN Límite Superior Normal (Normal Upper Limit) 
MO Bone Marrow 
MSC Mesenchymal Cells 
MSV Mesenchymal Cells of Valladolid (IBGM Procedure) 
Non-steroidal Anti-inflammatory NSAIDs * 
PCUVa Scientific Park of the University of Valladolid 
PEI Research Product 
SOPs Standard Operating Procedures 
PRP Platelet Rich Plasma 
ROI Region of Interest 
QC Quality Control 
SDV Source data verification 
UVa University of Valladolid 


                                         Disc_allo_MSV protocol. v.1.6 1                             2 
 
* NSAIDs stands for “nonsteroidal anti-inflammatory drugs”, sometimes abbreviated as 
well NAIDs 
 
INDEX: 
Title page..….1 
Signature pages..…...2 
Emergency telephone numbers. ... 6 
List of Abbreviations...... 7 
Index........ 8 
1. SUMMARY OF THE CLINICAL TRIAL ........ 11 
2. JUSTIFICATIONS OF THE TEST AND ITS DESIGN ............. 14 
2.1 SUMMARY .............. .14 
2.2 EPIDEMIOLOGY OF GONARTHROSIS. ECONOMIC AND SOCIAL IMPACT ........ 
15 
2.3 PATHOPHYSIOLOGY OF THE INTERVERTEBRAL DISC AND LUMBAR 
DEGENERATIVE DISCOPATHY ........ 15 
2.4 CURRENT TREATMENTS OF DEGENERATIVE DISCOPATHY ............ 17 
2.5 BACKGROUND OF CELLULAR THERAPY ……...... 19 
2.6 PROPOSED ALTERNATIVE TREATMENT ...................20 
2.6.1 General characteristics of the product under study ......20 
2.6.2 Obtaining, cultivating, expanding and applying MSV …………… 21 
2.6.3 Possible complications derived from the proposed therapy ...............21 
2.7 BIBLIOGRAPHICAL BACKGROUND SUPPORTING SAFETY AND 
THERAPEUTIC EFFECTIVENESS ... 21 
2.8 EXPERIENCE OF THE RESEARCH TEAM …………….... 23 
3.1 Main objective ............ 24 
3.2 Secondary objectives ........................ 24 
3.3 Primary criteria ............... 24 
3.4 Secondary criteria .......... 24 
4. TYPE OF CLINICAL TRIAL AND DESIGN OF THE SAME ....................... 25 
4.1 Type of test .................. 25 
4.2 Overall study design ....................... 25 
5. SELECTION OF PATIENTS ........................ 27 
5.1 INCLUSION AND EXCLUSION CRITERIA .......................27 
5.1.1 Inclusion criteria ........................ 27 
5.1.2 Exclusion criteria .................. 27 
5.2 DIAGNOSTIC AND FOLLOW-UP CRITERIA FOR THE PATHOLOGY UNDER 
STUDY ................ 28 
5.2.1 Clinical criteria ...................... 28 
5.2.2 Criteria per image ........................... 28 
5.2.2.1 Radiography .................................. 28 
5.2.2.2 Magnetic resonance imaging (MRI) ..................... 28 
5.2.3 Laboratory Analysis ...................................... 28 
5.2.4 Anatomopathological Study ...................................... 28 
5.3. SELECTION OF DONORS OF MESENCHYMAL CELLS …………… ..29 
5.3.1. Inclusion criteria ………………………………… 29 
5.3.2. Exclusion criteria …………………… ..29 
5.3.3. Procedure ……………………… ... 29 
5.4 NUMBER OF EXPECTED PATIENTS AND RATIONALE ..................... 29 
5.5 CRITERIA FOR NON-RESPONSE TO TREATMENT ......................... 29 
5.6 CRITERIA FOR WITHDRAWAL OF PATIENTS AND PROCEDURES TO FOLLOW 
........... 29 
5.7 PATIENT REPLACEMENT CRITERIA ... 30 
5.8. FOLLOW-UP OF PATIENTS …………………… ..30 
5.9 STUDY PARTICIPATION CARD …………. ……… .31 


                                         Disc_allo_MSV protocol. v.1.6 1                             3 
 
5.10 TEST DURATION ............................. 316. TREATMENT AND STUDY 
PROCEDURES ......................... 32 
6.1 PRODUCT IN RESEARCH AND REFERENCE THERAPY .............. 32 
6.1.1 Obtaining, cultivating and expanding MSV ................. 32 
6.1.2 Packaging and transport for shipment ..................... 33 
6.1.3 Application of cells .......................... ............................... 33 
6.1.4 Post-treatment guideline ................................ .................................. 33 
6.1.5 Possible complications derived from the proposed therapy ………………… 34 
6.1.6 Methodology for obtaining bone marrow from donors ……………….… 34 
6.2 ASSIGNMENT OF TREATMENT ...................................... 35 
6.2.1 Numerical correspondence of patients .............. 35 
6.2.2 Randomization numbers ................................... 35 
6.3 CONCOMITATING TREATMENTS .......................... 35 
6.4 DRUG ACCOUNTING ........................... ........ 35 
6.5 MANAGEMENT OF STUDY MEDICATION ................................. 35 
7. DEVELOPMENT OF THE TEST AND ASSESSMENT OF THE RESPONSE ............. 
36 
7.1 ASSESSMENT OF THE RESPONSE .................. 36 
7.1.1. Main evaluation variable .............. 36 
7.1.2. Secondary evaluation variable ........................ 36 
7.2 TEST SCHEDULE .......................... 36 
7.2.1. Visiting program ………………………………………..37 
8. ADVERSE EVENTS .................................................. 38 
8.1 ADVERSE EVENTS (AA) ................................ 38 
8.1. Definition .......................................................................... .. 38 
8.2. Description of adverse events ....................... . 38 
8.3 Record of Adverse Events .............................. ........... 39 
8.4 Serious Adverse Event (AAG) ..................................... .............. 40 
9. ETHICAL ASPECTS ................... 41 
9.1 ETHICAL AND REGULATORY REQUIREMENTS .................. ... 41 
9.1.1 Investigator Responsibilities ......................... 41 
9.1.2 Informed Consent ............................................. 41 
9.1.3 Approval of the Clinical Research Ethics Committee (CEIC) ................................ 
41 
9.1.4 Approval of the Health Authorities ............................... 42 
9.2 MODIFICATIONS OF THE PROTOCOL ..................... 42 
9.3 INSURANCE POLICY .................................................. 42 
9.4 ACCESS TO PATIENT DATA ............... 42 
10. PRACTICAL CONSIDERATIONS ..................................... 43 
10.1 RESPONSIBILITIES OF THE VARIOUS PARTICIPANTS IN THE TRIAL 
.......................... 43 
10.1.1 Researcher ........................... 43 
10.1.2 Monitor ..................... 43 
10.1.3 Promoter .............................................. ..43 
10.2 DATA REVIEW ..................................................... 43 
10.2.1 Center monitoring ……................... 43 
10.3 DATA COLLECTION ......................................... 43 
10.3.1 Data collection notebook (CRD) ........................................ 43 
10.3.2 Original data ............................................................. 44 
10.4 DATA CONSERVATION AND RECORD KEEPING ......................... 44 
10.5 QUALITY CONTROL ................................................................ 44 
10.6 INSPECTIONS AND AUDITS ........................................................ 44 
10.7 PRESENTATION AND PUBLICATION ....................................45 
11. STATISTICAL ANALYSIS .............................................45 
11.1 SAMPLE SIZE ..........................................45 


                                         Disc_allo_MSV protocol. v.1.6 1                             4 
 
11.2 STATISTICAL METHOD USED .................45 
11.2.1 Main objectives, main variables ...........45 
11.2.1.1 Radiographic criteria ...................45 
11.2.1.1 Quantitative MRI Criteria ..................................... 46 
11.3 POPULATION AND ANALYSIS ........................................ 46 
11.3.1 Evaluable patients ..................................... 46 
11.3.2 Efficacy population (Per protocol (PP) population): ......................... 46 
11.3.3 "Security Population ........................................ 46 
11.3.4 Methods of analysis ................................... 46 
11.3.5 Background and demographic characteristics ............................. 46 
11.3.6 Security ...................... ..47 
11.3.7 Efficacy ................... 47 
11.4 Software ……............ .47 
11.5. Difficulties and limitations of the study …………………... 47 
12. BIBLIOGRAPHIC REFERENCES ................................. 48 
 
ANNEXES: 
ANNEX I: PRODUCT DOSSIER AND INVESTIGATOR'S MANUAL ................ A1 
ANNEX II: PATIENT INFORMATION SHEET AND CONSENT DOCUMENTS 
INFORMED …………….… A4 
ANNEX III: DECLARATION OF HELSINKI .................. A13 
ANNEX IV: SERIOUS ADVERSE EVENTS NOTIFICATION SHEET ..................... A17 
ANNEX V: VISUAL ANALOGUE SCALE (VAS) OF LUMBAR AND SCIATIC PAIN 
…………A19 
APPENDIXVI: OSWESTRY DISABILITY INDEX .......................................A20 
APPENDIXVII: SF-12 HEALTH QUESTIONNAIRE ........................ A22 
ANNEX VIII: MODIC CHANGES .................... A24 
ANNEX IX: RESEARCHER SIGNATURES PAGES .......................... A25 
ANNEX X: INSURANCE POLICY ............................ A26 
ANNEX XI: INSURANCE CERTIFICATE (Art.8; RD223 / 2004) .......................... A27 
 
 
 


                                         Disc_allo_MSV protocol. v.1.6 1                             5 
 
1. SUMMARY 
Type of request: 
Phase I-II, single-center, prospective, randomized, blinded ** and controlled clinical trial 
for the treatment of lumbar degenerative disc disease with allogeneic mesenchymal 
cells (MSV *), with two arms with 12 patients each. In the experimental arm, cells will 
be administered locally in the nucleus pulposus area of the affected segment "Ex Vivo" 
expanded allogeneic mesenchymal cells with the IBGM GMP procedure (MSV; PEI No. 
10-134; authorized by the AEMPS). The control arm will infiltrate the area of the 
paravertebral musculature close to the injury with saline solution containing 
mepivacaine at 1% in the same volume and subject to the same maneuvers as the 
intervention on the arm experimental. 
** Double blind, masked for the patient and evaluators performing the analysis of the 
results, open to the doctor who applies the cells. 
 
Data relating to the Sponsor:  
Citospin, 
Scientific Park of the University of Valladolid 
R + D Building, Paseo de Belén, 11 
Campus Miguel Delibes 
47011 Valladolid 
NIF: NIF. B-47673538 
Title of the clinical trial: 
Treatment of lumbar degenerative disc disease with allogeneic mesenchymal cells 
(MSV *). * MSV = Mesenchymal cells of the bone marrow prepared by the procedure of 
IBGM of Valladolid. 
 
Protocol Code: Disc_allo_MSV 
Eudra-CT: 2012-004444-30 
 
Experimental and control drug: dose, pharmaceutical form, route of 
administration, therapeutic group: 
Experimental drug: The investigational drug or product is MSV, which is 
Mesenchymal bone marrow stromal cells obtained from healthy donors with negative 
serology (NAT; nucleic acid technology) and processed according to procedure of the 
IBGM (PEI Num. 10-134; approved by AEMPS), with the following characteristics: 
 Cell dose: 25x10e6 ± 5x10e6 MSV per disk. 
 Presentation: 2 ml of cell suspension in Ringer-lactate isotonic with 0.5% human 
albumin and 5 mM glucose in a 5 ml syringe. Stability:> 12 hours at 4-20 ºC 
 Administration: Injection into the nucleus pulposus area of the affected disc 
 Therapeutic Group: Cell Therapy 
Control drug: Injection of 2 ml of 1% mepivacaine in saline serum (see section 2.4). in 
the paravertebral musculature close to the injury, using the same volume and the same 
maneuvers as the intervention in the experimental arm. 
Cell Production 
Citospin, Cell Production Unit, Scientific Park of the University of Valladolid, R + D 
Building, Campus Miguel Delibes, Paseo de Belén, nº 11, 47011 Valladolid. Tel. 
983184827. Technical Director: Dra. Ana García Sánchez  
Phase of the clinical trial 
Phase I-II 
Objectives: 
Main goal: 
 Evaluate the feasibility and safety of the local use of allogeneic MSV for the 
treatment of lumbar degenerative disc disease. 
Secondary objectives: 


                                         Disc_allo_MSV protocol. v.1.6 1                             6 
 
 Evaluate the efficacy of allogeneic MSV treatments using criteria of clinical evolution 
objectified by the low back pain questionnaires (Visual Scale Analog, VAS), disability 
(Oswestry questionnaire) and quality of life (questionnaire SF-36 in its abbreviated 
version, SF-12). 
 Follow-up of the evolution of disc dehydration by the images of MRI calibrated at T2. 
 Compare the efficacy of the treatments in the control and experimental arms. 
Total number of patients 
The number of patients treated will be 24, 12 for each of the branches. 
Participating countries 
The study will be carried out at the Hospital Clínico Universitario de Valladolid. Avda. 
Ramón y Cajal nº 3, 47003 Valladolid, Spain 
Treatment duration 
The implantation will be carried out in a single session and the evolution of the patients 
for 12 months. 
Schedule and expected completion date 
Start of study: last quarter of 2012 
Recruitment: for a maximum of 6 months, until 12 patients are obtained for each 
branch. 
Duration of the trial: 12 months after the treatment of the last patient. 
 
2. JUSTIFICATION OF THE TEST AND ITS DESIGN 
2.1. ABSTRACT 
Intervertebral disc degeneration is a very common disease, which can lead to origin to 
low back pain, radiculopathy or myelopathy. The combination of physical treatment and 
The doctor solves 90% of the cases, but 10% becomes chronic, generating a serious 
health problem, since chronic low back pain spoils both the quality of life of the patient 
as their work capacity, with an enormous economic impact on the System of Health. 
Chronic cases often require surgery, which usually relieves pain, but gives lead to 
adverse effects on mobility and accelerate degeneration of the segments adjacent 
vertebral bodies. We have recently published the results of the pilot study with our 
autologous mesenchymal cells (MSV), demonstrating its feasibility and safety, and 
remarkable clinical efficacy (71% of optimal effect after 12 months), which compares 
favorably with surgical treatment (arthrodesis or disc replacement), but MSV treatment 
is much simpler and more conservative (Orozco et al., 2011). Yes If it were possible to 
use allogeneic MSVs, it would be greatly simplified and the cost of treatment, 
considerably increasing the number of patients who could benefit from it. On the other 
hand, data from the literature show that mesenchymal cells, due to their low 
antigenicity and immunomodulatory effect, escape to antigen recognition and are 
tolerated by the recipient's immune system. This Tolerance has been extensively 
studied in animal models and, more recently, has been has demonstrated the feasibility 
and safety of mesenchymal cell treatments allogeneic in humans, with the completion 
of several published phase II trials and several dozens declared in the NIH database in 
the recruitment or implementation phase. Us We ourselves have an allogeneic MSV 
trial underway, exactly the same product proposed here, for the treatment of knee 
osteoarthritis (Eudra-CT: 2011-005321-51). In the present proposal, a prospective 
phase I-II clinical trial is proposed. randomized, blinded and controlled, with 2 arms of 
12 patients each. 
In the arm experimental mesenchymal cells obtained from healthy donors purified and 
expanded under GMP conditions using our protocol, authorized by the AEMPS (MSV, 
PEI No. 10-134). MSVs will infiltrate the affected intervertebral discs. Whenever 
possible (because there is sufficient material and explicit consent), use surplus cells 
from patients undergoing MSV therapy as donors autologous, which would significantly 
simplify the procedure. In the control arm it will infiltrate the area of the paravertebral 
musculature near the injury with saline solution containing 1% mepivacaine in the same 
volume and subject to the same maneuvers as the intervention in the experimental 


                                         Disc_allo_MSV protocol. v.1.6 1                             7 
 
arm. Study participants will be offered the possibility of receiving MSV treatment once 
the study is completed if it is demonstrated beneficial and the patient so wishes. The 
application of the cells will be carried out in the Valladolid University Clinical Hospital. 
The evaluation of the response to treatment will be blind and will be followed by the 
evolution of the indices of low back pain, disability and quality of life, as well as the 
improvement of the dehydration of the treated segments, quantified from magnetic 
resonance images (T2 sequence). 
2.2. EPIDEMIOLOGY OF DEGENERATIVE DISC DISEASE. REPERCUSSION 
ECONOMIC AND SOCIAL. 
Intervertebral disc degeneration is a very common disease, seen in 80% of the 
subjects older than 60 years. Most of these individuals are asymptomatic, but in some 
of them it can lead to axial skeletal pain, radiculopathy and myelopathy. Combining 
physical and medical therapies is successful in relief of pain in about 90% of cases. 
However, the remaining 10% is chronic and generate a serious public health problem, 
since chronic low back pain ruins both the quality of life and the work capacity of the 
patient and increases the use of health services (Errico et al., 2004; Balague et al., 
2007). Chronic low back pain is one of the most prevalent pathologies in the countries 
industrialized: 75% of the population has suffered it at some time and, although 90% 
are cured In 3 months, 10% become chronic, which represents 5-6 million people in 
Spain and 67 million in the EU (http://www.zimmer2.eu/lancs/incidence_backpain.html). 
CL is a very important cause of absenteeism, which is required for 59% of the patients. 
It is estimated that it is the second in importance, with 700,000 days / year in the EU. It 
also promotes an overuse of the health system, both in the use of physical means (for 
example RX), as in medication (90% of patients use drugs). On the whole, It is 
estimated that it represents 1-3% of health spending in the EU 
(http://www.zimmer2.eu/lancs/incidence_backpain.html). In Spain it is estimated that an 
expense of about 6,000 million euros per year (Robaina, 2006). The intervention 
surgery (usually arthrodesis), which is applied to about 1000 patients per year in Spain 
is the "gold standard" to solve the problem of pain, but it is an expense considerable 
and is not free of side effects, so its systematic use is a highly controversial topic 
(Errico et al., 2004; Airaksinen et al., 2006; Kwon et al., 2006; Harrop et al., 2008). 
 
2.3. PATHOPHYSIOLOGY OF THE INTERVERTEBRAL DISC (IVD) AND 
DISCOPATHY LUMBAR DEGENERATIVE (DDL). 
The intervertebral disc (IVD) is made up of two basic components, the annulus fibrosus 
(AF) and the nucleus pulposus (NP), separated by a transition zone. The fibrous ring 
The outer layer is made up of about 25 layers of type I collagen (70-80%) that are 
oriented following an angle of 60º between adjacent vertebrae, and by cells of the 
fibrocyte / fibroblast arranged concentrically with a density of 9x106 cells / cm3. The 
non-elastic collagen fibers of each layer insert into the bodies adjacent vertebral 
bodies. In the transition zone the fibrosites are being replaced by chondrocytes and 
type II collagen, elastic, by type I collagen, highly resistant to distention (Eyre & Muir, 
1976; Nerlich et al., 1998) NP contains collagen (80% type II), notochord-derived cells 
similar to chondrocytes and polyglycans. Its composition is similar to that of hyaline 
cartilage although with more polyglycans and a different proportion of them. It has no 
vascularity and the number of cells per unit volume is very small, about 4x106 cells / 
cm3 (Roughley, 2004; Zhao et al., 2007). NP cells are adapted to live at low oxygen 
tension, low glucose concentration and low pH (Urban et al., 2004; Bibby et al., 2005). 
In fact, it has been proven "In Vitro" that very low oxygen levels induce the 
differentiation of mesenchymal cells towards cell-specific phenotypes nucleus pulposus 
(Horner & Urban, 2001; Bibby et al., 2005). 
Collagen fibers confer tensile strength and proteoglycans are responsible for the ability 
to retain water and ultimately the firmness and compressive strength. The water 
content varies depending on the external load to which DIV is submitted. In high load 
situations the water is squeezed into the saucers adjacent vertebral bodies (endplates, 


                                         Disc_allo_MSV protocol. v.1.6 1                             8 
 
containing a 1 mm layer of cartilage thickness) and instead returns to the disc in low 
load situations. For this mechanism works it is essential that the nucleus pulposus 
maintains its hydrophilic nature, It depends mostly on proteoglycans. The mechanism 
of water exchange through of the end plates is necessary for the maintenance of the 
PN, which is avascular, since that nutrients and waste products are incorporated and 
removed by diffusion to and from the vessels of the outer ring and vertebral body 
(Sztrolovics et al., 2002). The End plates also act as physical barriers to prevent core 
intrusion pulposus in the trabecular bone of the vertebral bodies. The vascularization 
and innervation of nondegenerate IVD is limited to the external fibrous ring at through 
the sinuvertebral nerve, which innervates the posterior and posterolateral regions and 
the gray branch, which is mainly distributed along its lateral and anterior areas. The 
nucleus pulposus has no innervation (Coppes et al., 1990). In degenerated discs, the 
number of nerve fibers and it is possible that cytokines produced in the NP reach, at 
through fissures produced in the AF, the nerve endings, producing their irritation 
chemistry (Aoki et al., 2002). 
The IVD distributes mechanical forces through the column, preserving its stability and 
giving it flexibility. From the age of 30 it is normal for radiology to show signs initials of 
vertebral osteoarthritis at some level of the spine. When the NP ages it is reduced the 
number of chondrocytes and the concentration of proteoglycans, and the disc is 
dehydrated with the consequent alteration of its physical properties, transforming from 
mucoid to fibrous and rigid. In the fibrous ring, the fibrillar organization deteriorates, 
forming channels that allow the contents of the NP to herniate through the ring. If 
degeneration disc is gradual, generally painless, and radiological signs can be seen 
without clinical translation. If the process develops abruptly, many times As a 
consequence of over-requests, it tends to give clinical symptoms. Possibly, the 
decreased damping capacity could facilitate the triggering of the neurological 
mechanism that can trigger pain. In conclusion it is thought that the NP is, in many 
cases, the starting point of the degenerative cascade and, therefore Consequently, it 
should be a priority point of therapeutic attention (Adams et al., 2000). 
2.4. CURRENT TREATMENTS FOR DEGENERATIVE DISCOPATHY. 
Disc degeneration has different clinical translations. May lead to herniation disc 
material and, depending on the location, generate symptoms ranging from isolated low 
back pain and / or associated with radiculopathy, myelopathy or claudication 
neurogenic disease associated with canal stenosis. According to the degree of invasion 
of the structures next we speak of protrusion or hernia. On many occasions, however, 
there is pain lumbar without herniation and with integrity of the fibrous ring. It is in these 
cases when proposes the treatment described in this RC. 
The first step of treatment includes physical measures for stabilization of the lumbar 
spine. Both by external means (girdles or corsets), and, mainly, by toning the 
abdominal and spinal muscles through exercises isometric that do not require 
mobilization of the lumbar spine. As a complement of these measures the weight will 
be controlled to an adequate level and measures will be implemented of postural 
hygiene: by using ergonomic chairs and furniture, avoiding flex the spine forward and 
keep the weights close to the body. The use of both non-steroidal anti-inflammatory 
drugs such as corticosteroids, analgesics and the Muscle relaxants may be helpful in 
periods of exacerbation of pain. The application of currents, massages, tractions and 
heat in rehabilitation and acupuncture can improve symptoms temporarily. The next 
step includes periarticular infiltrations of local anesthetic and corticosteroids, which can 
serve both as a diagnosis of the origin of the pain and treatment of the acute phase. 
The final step is surgery, in which the lumbar spine is stabilized by fixing the affected 
vertebrae. Surgical treatment is necessary when the condition clinical is intense and 
refractory to drug and rehabilitation treatments. The discectomy associated or not with 
vertebral segment arthrodesis is the “gold standard” and its efficacy is beyond question 
(Errico et al., 2004; Kwon et al., 2006). Fixing is done with the patient's own bone graft 
and is facilitated with metal implants. On discs degenerates expressed as a protrusion 


                                         Disc_allo_MSV protocol. v.1.6 1                             9 
 
or contained herniated disc can be considered percutaneous nucleotomy performed 
under fluoroscopic control, either mechanical, electrothermal or chemical 
(chymopapain, DiscoGel). Surgical interventions usually have very satisfactory 
analgesic effects, but are inevitably iatrogenic, reducing mobility and destabilizing 
neighboring segments, even when these effects are sometimes subclinical (Hilibrand & 
Robbins, 2004; Harrop et al., 2008; Rihn et al., 2009). 
The interest in preserving the mobility of the affected segment led to the development 
of prostheses of disk. In the early stages of disc degeneration, nucleus pulposus 
implants, they can occupy the therapeutic space between discectomy and arthrodesis. 
Ideally, they are capable of recovering the turgor of the disc, the tension of the fibrous 
ring and the ability to distribute loads evenly across the disc space. Most designs use 
viscoelastic polymers that are injected into the disc space (Strange & Oyen, 2012). 
In Figure 1 we compare the therapeutic efficacy of different procedures in seven recent 
high-quality clinical trials. Data on the evolution of pain and disability have been 
calculated and expressed on a scale of 0-100% and the comparison of The treatments 
have been carried out by comparing the slope of the line that relates relief of the pain 
versus initial pain (Huskisson, 1974). The slope of the line defines the efficiency of any 
particular treatment, this maximum being when a slope of 1 (Total relief, Figure 1). 
Details of the analysis can be found in the publication original (Orozco et al., 2011). 
Exercise, conventional "non-surgical" treatment plus Common, it was the least potent 
treatment, with an efficacy of 0.07 (Fritzell et al., 2001). The efficacy of treatments 
involving cognitive intervention and exercise ranged between 0.20 and 0.29 (Brox et 
al., 2003; Fairbank et al., 2005; Brox et al., 2006), and the protocols of spinal fusion 
were the most effective, with an efficacy ranging from 0.30 to 0.71 in different trials 
(Fritzell et al., 2001; Brox et al., 2003; Fairbank et al., 2005; Hohaus et al., 2008; Guyer 
et al., 2009). Disc replacement protocols with artificial discs had the same efficacy as 
fusion alone (Guyer et al., 2009; Siepe et al., 2009). Finally, In one trial, the effects of 
discectomy were compared to discectomy plus treatment with expanded cells in the 
excised disc material (ADCT in Figure 1) a small but significant improvement was 
found in this group, although only after 2 years (Hohaus et al., 2008). This figure also 
represents the results obtained recently by us with autologous MSVs (Dotted curve 
marked “This study”) (Orozco et al., 2011). The efficacy reached a value of 0.71, a 
value indistinguishable from the maximums reached with surgical treatments (see 
discussion in the section next ahead). 
 
2.5. BACKGROUND OF CELLULAR THERAPY. 
Advances in understanding the pathophysiology of degenerative disc disease have 
promoted the study of new biological therapies, including cell therapy. The Potential 
advantages of these treatments are the preservation of anatomy, biomechanics, and 
the normal movement of the areas near the injury. Cell therapy, especially with 
mesenchymal cells (MSC), has produced interesting results in both in vitro and in vivo 
(Fassett et al., 2009). Co-culturing MSC with extracted cells nucleus pulposus (NP) 
stimulates the proliferation of nucleus pulposus cells and the differentiation of MSCs 
towards the chondrogenic lineage (Vadala et al., 2008; Yang et al., 2008; Le Maitre et 
al., 2009; Watanabe et al., 2009). Increased production of cytokines, in particular 
TGFβ, favors these transformations (Risbud et al., 2004; Yang et al., 2008; Yang et al., 
2010). The nucleus pulposus contains MSCs that are very similar to the MSCs 
obtained from bone marrow (Blanco et al., 2010), and studies in animal models of disc 
degeneration have shown that MSCs injected into the nucleus area pulposus survive 
for months, and even proliferate in canine models (Hiyama et al., 2008; Blanco et al., 
2010), porcine (Henriksson et al., 2009), and rabbit (Sakai et al., 2005). In addition, the 
transplanted MSCs induced the production of matrix proteins. extracellular, including 
aggrecan and other proteoglycans, and types I and II collagen (Sakai et al., 2005; 
Hohaus et al., 2008; Henriksson et al., 2009). Finally, these studies of the height and 
water content of the disc (Sakai et al., 2005; Hiyama et al., 2008; Hohaus et al., 2008). 


                                         Disc_allo_MSV protocol. v.1.6 1                             10 
 
We recently conducted a pilot study in humans with autologous MSCs (Orozco et al., 
2001). Our results demonstrated the feasibility and safety of the procedure and 
indicated an efficacy close to 71%, which compares favorably with other procedures 
(Figure 1). A small rehydration was also documented but significant number of affected 
discs after one year of treatment (Orozco et al., 2011). The procedure is very attractive, 
as it equals in efficacy to arthrodesis, the gold-standard of current therapeutic 
procedures, but it is much more conservative, preserves the normal biomechanics and 
does not require surgery or hospitalization of the patient. The use of cells However, 
autologous makes the procedure very time consuming and expensive. 
The use of allogeneic cells in cell therapy procedures would expand noticeably its 
horizon, since it would simplify the procedure, improve the yields and would lower 
costs, making treatment accessible to much broader layers of the population. 
Disadvantages include the possibility of rejection by the immune system, as is well 
known in the case of transplants. In the case of MSCs we have, without However, a 
favorable circumstance, and it is the repeatedly proven fact that these cells evade 
antigen recognition and, furthermore, inhibit responses immune in a way not restricted 
by the HLA system, leading to tolerance immunological (Le Blanc et al., 2003; 
Aggarwal & Pittenger, 2005; Jiang et al., 2005; Klyushnenkova et al., 2005; 
Sotiropoulou et al., 2006; Le Blanc & Ringden, 2007; Sotiropoulou & Papamichail, 
2007). In animal experimentation, repeatedly allogeneic MSCs without any indication of 
rejection or immune problems later. Circumscribing the evidence to studies regarding 
the regeneration of cartilage, we have examples in rabbit models (Yan & Yu, 2007; 
Miyamoto et al., 2010; Dashtdar et al., 2011) and pig (Shimomura et al., 2010; Chang 
et al., 2011). The safety of allogeneic mesenchymal cells has recently been shown also 
in humans, where the results obtained in two clinical trials for the treatment of systemic 
lupus erythematosus, no adverse effects after administration endovenous (Sun et al., 
2009; Liang et al., 2010). Results have recently been obtained similar with cord blood 
derived allogeneic mesenchymal cells (Sun et al., 2010). 
There are also numerous treated cases of breast cancer patients (Koc et al., 2000), 
graft versus host disease (Lazarus et al., 2005), and other diseases autoimmune 
(Bernardo et al., 2009; Bernardo et al., 2011) without there having been, until now, 
adverse effects. Finally, there are declared 69 clinical trials using MSC  allogeneic in 
the database "clinicaltrials.gov" for the treatment of very pathologies varied, including 
not just graft versus host disease and different autoimmune diseases, but also 
ischemic strokes of the brain, heart or peripherals, liver destruction, osteogenesis 
imperfecta, or disc degeneration intervertebral (see 
http://clinicaltrials.gov/ct2/results?term=mesenchymal+allogenic). On summary, both 
the experience of animal experimentation and use in trials Clinical trials in humans 
demonstrate the safety of allogeneic mesenchymal cells, without adverse effects have 
been reported. These antecedents, together with the notable benefits for patients that 
its use would bring fully justify its use in the proposed essay. 
2.6. PROPOSED ALTERNATIVE TREATMENT. 
Based on all of the above, we propose a clinical trial with two arms: 
1) Experimental group: treatment with allogeneic MSV from donors, with informed 
consent, isolated and expanded as described in our protocol (PEI No. 10-134; see 
details below). Expand following the GMP procedure until obtaining 25x106 cells (about 
3 weeks), that are processed and managed as detailed below. 
2) Control group: Injection in the area of the paravertebral muscles close to the lesion 
of saline serum containing 1% mepivacaine in identical volume and subject to the same 
maneuvers as the intervention in the experimental arm. 
The proposed treatment is based on our own previous trial, using Autologous MSVs 
(Orozco et al., 2011), but in this case we propose to use cells allogeneic, which would 
simplify and make the procedure cheaper, making it much more universal. Previous 
experience with allogeneic MSCs (including our own experience in the ongoing Eudra 


                                         Disc_allo_MSV protocol. v.1.6 1                             11 
 
CT 2011-0053221-51) has shown no adverse effects, even in parenteral administration 
circumstances (see below) 
2.6.1 General characteristics of the product under study. The investigational drug 
or product (experimental arm) is MSV, which is bone marrow mesenchymal cells 
processed according to the IBGM system of Valladolid, suspended in isotonic Ringer-
lactate medium with 0.5% human albumin and 5 mM glucose. Cell dose: 25x106 ± 
5x106 MSV, in a volume of 2 ml of cell suspension. Stability demonstrated is> 12 hours 
at 4-20 ºC. The whole process of obtaining MSV is carried out by highly qualified 
specialists in crops cell phones and is developed in the Cell Production Unit of Citospin 
(Parque Científico de la UVa), meeting GMP criteria and following protocols approved 
by the AEMPS (PEI No. 10-134). 
In the validations carried out, MSV has been shown to possess the characteristics 
typical MSC defined by the Society for Cellular Therapy (Dominici et al., 2006): 1) 
Adherence to plastic in cultivation; 2) Expression of CD73, CD90 and CD105 antigens. 
3) Absence of hematopoietic antigens, markers of monocytes, macrophages and B 
lymphocytes. 4) In vitro differentiation capacity in osteoblasts, adipocytes and 
chondrocytes. Watch details in Figure 2 and Figure 3. 
2.6.2. Obtaining, cultivation and expansion and application of MSV. 
These matters are described in the section dedicated to the treatment, product of 
research and study procedures, sections 6.1.2 to 6.1.4. 
2.6.3. Possible complications derived from the proposed therapy. Complications 
are similar to those of discography, and they occur very rarely. The most common 
complaint is exacerbation of pain for 1-2 weeks, which usually resolved by analgesia 
and muscle relaxants for a period short. The most serious complication is discitis, the 
incidence of which is less than 0.1% (Osti et al., 1990). Other complications described, 
although much less frequently, are transient headache, nausea, meningitis, epidural 
abscess, arachnoiditis, bruising intrathecal, retroperitoneal hematoma, cauda equina 
syndrome and acute disc herniation. Isolated cases of rash are not considered in this 
trial, as they are attributable to contrast medium. Initial fears about possible long-term 
discography side effects regarding disc viability have not been confirmed.  
In a study with up to 20 years of clinical follow-up, no radiographic evidence of disc 
degeneration was found progressive after discographies (Flanagan & Chung, 1986). 
The possible risk of complications derived from the use of allogeneic cells has been 
discussed in detail above. Suffice now to summarize that, according to the literature, 
the application of Allogeneic MSCs, both locally and systemically, have been shown to 
be safe both in the context of clinical trials and studies in animal models. Either way, 
will monitor skin and mucosal reactivity to watch for a possible immune reaction. 
2.7 BIBLIOGRAPHICAL BACKGROUND SUPPORTING SAFETY AND 
EFFECTIVENESS THERAPY. 
Studies in animal models of disc degeneration have shown that MSCs injected into the 
nucleus pulposus area survive for months and even proliferate in the canine model 
(Hiyama et al., 2008; Blanco et al., 2010), porcine (Henriksson et al., 2009), and rabbit 
(Sakai et al., 2005). In addition, the transplanted MSCs induced the production of 
extracellular matrix proteins, including aggrecan and other proteoglycans, and collagen 
types I and II (Sakai et al., 2005; Hohaus et al., 2008; Henriksson et al., 2009). Finally, 
these studies also showed evidence of therapeutic efficacy, since the injection of the 
MSC resulted in a better preservation of the height and water content of the disk (Sakai 
et al., 2005; Hiyama et al., 2008; Hohaus et al., 2008). Very recently, we have 
conducted a pilot study in humans with autologous MSCs. Our results demonstrated 
the feasibility and safety of the procedure and indicated an efficacy close to 71%, which 
compares favorably with other procedures (Figure 1). In addition, a small but significant 
rehydration of the affected discs after one year of treatment (Orozco et al., 2011). The 
process is very attractive, as it equates in efficacy to arthrodesis, the gold standard of 
procedures current therapeutics, but it is much more conservative, preserves normal 
biomechanics and it does not require surgery or hospitalization of the patient. The use 


                                         Disc_allo_MSV protocol. v.1.6 1                             12 
 
of autologous cells does, without However, the procedure is very time consuming and 
expensive, which makes it highly desirable investigate the possibility of allogeneic cells. 
In an ongoing clinical trial (Eudra CT 2011-005321-51; NCT01586312) we are already 
testing the effects of allogeneic MSV, with good preliminary results. The study 
proposed here, studying allogeneic MSV as a therapeutic alternative to degenerative 
disc disease and including a control group, which considerably increases the power of 
the trial with respect to the previous one (Orozco et al., 2011) for two reasons: 1) The 
possibility of comparison with a controlled group, and 2) The potential versatility added 
by include a group with allogeneic cells. This last aspect deserves additional comment, 
which is developed in the next paragraph. 
The use of allogeneic cells in cell therapy procedures would expand noticeably its 
horizon, since it would simplify the procedure, improve the yields and would lower 
costs, making treatment accessible to much broader layers of the population,. 
Disadvantages include the possibility of rejection by the immune system, as is well 
known in the case of transplants. In the case of MSCs we have, without However, a 
favorable circumstance, and it is the repeatedly proven fact that these cells evade 
antigen recognition and, furthermore, inhibit responses immune in a way not restricted 
by the HLA system, leading to tolerance immunological (Le Blanc et al., 2003; 
Aggarwal & Pittenger, 2005; Jiang et al., 2005; Klyushnenkova et al., 2005; 
Sotiropoulou et al., 2006; Le Blanc & Ringden, 2007; Sotiropoulou & Papamichail, 
2007). In animal experimentation, repeatedly allogeneic MSCs without any indication of 
rejection or immune problems later. Circumscribing the evidence to studies regarding 
the regeneration of cartilage, we have examples in rabbit models (Yan & Yu, 2007; 
Miyamoto et al., 2010; Dashtdar et al., 2011) and pig (Shimomura et al., 2010; Chang 
et al., 2011). The safety of allogeneic mesenchymal cells has recently also been 
demonstrated in humans, where the results obtained in two clinical trials for the 
treatment of systemic lupus erythematosus, no adverse effects after administration 
endovenous (Sun et al., 2009; Liang et al., 2010). 
Results have recently been obtained similar with cord blood derived allogeneic 
mesenchymal cells (Sun et al., 2010) .There are also numerous treated cases of 
patients with breast cancer (Koc et al., 2000) graft versus host disease (Lazarus et al., 
2005), and other diseases autoimmune (Bernardo et al., 2009; Bernardo et al., 2011) 
without there having been, until now, adverse effects. Finally, there are declared 69 
clinical trials using MSC allogeneic in the database "clinicaltrials.gov" for the treatment 
of very pathologies varied, including not just graft versus host disease and different 
autoimmune diseases, but also ischemic strokes of the brain, heart or peripherals, liver 
destruction, osteogenesis imperfecta, or disc degeneration intervertebral (see 
http://clinicaltrials.gov/ct2/results?term=mesenchymal+allogenic). On summary, both 
the experience of animal experimentation and use in trials Clinical trials in humans 
demonstrate the safety of allogeneic mesenchymal cells, no adverse effects have been 
reported. These antecedents, together with the notable benefits for patients that its use 
would bring fully justify its use in the proposed essay. 
 
2.8 EXPERIENCE OF THE RESEARCH TEAM. 
The research team has experience in both cell production and preclinical and clinical 
research with mesenchymal cells, with a run of several years of preclinical-clinical 
collaboration in research projects. The team will be coordinated by Dr. Javier García-
Sancho, who has been the coordinator of the Cell Therapy Network of the Carlos III 
Health Institute (TerCel) for 8 years and that directs the Valladolid node, of the that 
depends on the Cell Production Unit for clinical use and the EBT Citospin. The doctor. 
García-Sancho has experience in managing research in Cell Therapy, both through 
preclinical and clinical level, and in the regulatory aspects of it. Has participated in 
numerous clinical trials. He is the corresponding author of the publication describing 
the use of autologous MSVs for the treatment of lumbar degenerative disc disease 
(EudraCT 2008-001191-68) (Orozco et al., 2011), and is the coordinating investigator 


                                         Disc_allo_MSV protocol. v.1.6 1                             13 
 
of a trial in March with allogeneic MSV for the treatment of knee osteoarthritis 
(MSV_Allo; Eudra-CT: 2011-005321-51; NCT01586312). The Cell Production Unit of 
the IBGM, according to GMPs, is directed by Dr. Ana Sanchez. It was the first Clean 
Room authorized by the AEMPS in the Public System of Health and is currently 
participating in six clinical trials, several of them with cells mesenchymals of the bone 
marrow. It has an MSC preparation protocol authorized by the AEMPS (PEI No. 10-
134, Valladolid mesenchymal cells; MSV). It has a stable staff trained in quality control, 
which includes 12 people. It has recently given rise to a Technology-Based Company 
owned by the University, Citospin S.L. which adds additional nuances to cell production 
and counts with new and modern facilities in the Science Park of the University of 
Valladolid. Doctors Mercedes Alberca and Verónica García Díaz have more than 3 
years of experience as Production Managers in our GMP room. The University Clinical 
Hospital team led by Dr. David Cesar Noriega Gonzalez, from the Traumatology and 
Orthopedics Service has extensive clinical experience in this specialty, especially in 
degenerative disc pathology with more than 10 years of dedication. It has been 
incorporated into preclinical and clinical studies of Cell Therapy in collaboration with the 
Valladolid Node of the TerCel Network within the framework of the Network 
Regenerative Therapy of Castilla y León. Dr. Ardura has 7 years of experience in the 
practice of the specialty. 
3. OBJECTIVES 
In this prospective study that will evaluate the feasibility and safety of local implantation 
in the nucleus pulposus area of allogeneic MSVs for the treatment of discopathy 
lumbar degenerative. The working hypothesis contemplated pursues the achievement 
of long-lasting analgesia and anti-inflammation and regeneration of degenerated IVD in 
degree enough to be objectifiable by questionnaires and image scans. The approach 
as a randomized and controlled trial will allow a study preliminary efficacy compared to 
the control arm, 
3.1. Main goal 
 To evaluate the viability and safety of allogeneic MSV, applied by percutaneous 
injection in the nucleus pulposus area for the treatment of lumbar degenerative disc 
disease, verifying that each of the the procedures established in the protocol and 
recording the possible adverse effects related to cell therapy and those that may arise 
for the duration of the clinical trial, whether or not related to the same. 
3.2. Secondary objectives 
 To determine clinical outcomes and image variations 
Radiographic and Magnetic Resonance, which denote anti-inflammation, regeneration 
or, on the contrary, progression of lumbar IVD deterioration, after 12 months after the 
implementation of MSV in the NP. 
 Compare the efficacy of MSV treatment with that obtained in the arm control. 
3.3. Primary Criteria 
3.3.1. Radiographic criteria 
 In profile radiography, carried out with the same technical characteristics and hourly 
(before noon), the height of the space will be measured intervertebral in millimeters, 
this being the variable that will be compared with measurements that occurred over 
time (6 and 12 months after implantation of MSV). An increase in height will be 
understood as rehydration disc associated with an increase in proteoglycans and 
cellularity of the NP. 
 
3.3.2 Magnetic Resonance Criteria 
 A quantitative assessment of the water content of the affected segments on T2 
images (Sakai et al., 2006; Hiyama et al., 2008; Watanabe et al., 2009), following the 
procedure below illustrated in Figure 4 (see foot for details) (Orozco et al., 2011). The 
initial values will be compared with those obtained 6 and 12 months after the 
intervention. 
3.4. Secondary criteria 


                                         Disc_allo_MSV protocol. v.1.6 1                             14 
 
 Clinical observations of the surgeon 
 Evaluation of lumbar pain and general health status according to the Visual Scale 
Analog (EVA, see Annex V). The score will be transformed to a scale 0-100% for 
analysis (Huskisson, 1974) 
 Disability assessment using the Oswestry questionnaire (Davidson & Keating, 2002) 
(ODI, see Annex VI). 
 Assessment of quality of life using the simplified version of the questionnaire Short 
Form-36 (Davidson & Keating, 2002). It has been shown that this simplification (SF-12; 
see Annex VII) has a statistical value that approximates much the complete test 
(Gandek et al., 1998). 
4. TYPE OF CLINICAL TRIAL AND DESIGN OF THE SAME 
4.1 Type of CT 
Phase I-II clinical trial, single-center, prospective, randomized, blinded **, controlled for 
the treatment of lumbar degenerative disc disease with intact fibrous ring proven by 
MRI, with two arms: a control arm with placebo treatment (injection of mepivacaine at 
1%) and another experimental arm treated with allogeneic MSV. This is the third 
application of a PEI consisting of Ex vivo expanded bone marrow mesenchymal cells 
(PEI No. 10-1349). In both cases, the product will be administered in a volume of 2 ml 
per injection in the nucleus pulposus area. 
** Double blind, masked for the patient and evaluators performing the analysis of the 
results, open to the doctor who applies the cells. 
4.2 Overall study design 
The study consists of 2 arms, one experimental with allogeneic MSV, and another 
control in the to be injected into the area of the paravertebral muscles near the injury 
saline serum containing 1% mepivacaine (1 ml of 2% mepivacaine + 1 ml of saline) in 
identical volume and subject to the same maneuvers as the intervention on the arm 
experimental. Participants in the study will be offered the possibility of, once completed 
the study, receive MSV treatment if it proves beneficial and the patient so wishes. The 
inclusion criteria in both arms are identical, but after recruiting patients will be randomly 
assigned to one of the treatments. The Cell manufacturing will be carried out by 
Citospin at the facilities of the Park Scientist of the UVa and the application and 
monitoring will be carried out at the Clinical Hospital University of Valladolid. 
24 patients diagnosed with low back pain and / or low back pain attributable to disc 
degeneration and evidence of proven continuity of the external fibrous ring in the 
magnetic resonance image. The patients will be evaluated clinically, by the previous 
imaging studies (X-ray and MRI). If they are considered inclusive, they will be provided 
with the information regarding the clinical trial and the "Patient Information Sheet" 
(Annex II), citing them for the Inclusion visit. In the "Inclusion Visit", if the patient 
decides to participate in the trial, they must sign the "Informed Consent Document" and 
a visit will be scheduled for the practice of MRI and radiographs, which will be 
considered the pattern on which the possible determinable changes in the controls at 6 
and 12 months. If you are MRI and X-rays have been recently performed and their 
characteristics are valid for the study, its repetition can be avoided. In this visit, basic 
analytics will also be requested, serology for HIV, lúes and hepatitis B and C, and a 
serum sample will be obtained that will be sent to the Cell Production Unit for filing in 
the Seroteca. Although the Positive serology is not a criterion for exclusion of the 
recipient in the present test, it will be performed for epidemiological and preventive 
purposes. At the next visit (V0), it will be verified that all the inclusion criteria persist 
and that no exclusion is presented and the patient will be randomized (blind for him) in 
one of the two treatment groups and the date of implantation of MSV (V1). Once the 
mobile application is made, the patients will be followed up safety and to determine 
efficacy as established in the visit program (V2 to V5, see later). 
5. SELECTION OF PATIENTS 
Patients diagnosed with low back pain and / or low back pain will be included in the 
clinical trial attributable to disc degeneration and evidencing the continuity of the 


                                         Disc_allo_MSV protocol. v.1.6 1                             15 
 
external fibrous ring verified by MRI. The goal is to complete 12 patients in each of the 
two groups. 
5.1 INCLUSION AND EXCLUSION CRITERIA 
5.1.1. Inclusion criteria 
1. Lumbar degenerative disc disease of one or two discs with predominance of pain 
lumbar and / or persistent sciatica after conservative treatment (medical and 
physiotherapy) of more than 6 months of evolution. 
2. Complete fibrous ring, capable of containing the cellular implant, demonstrated with 
in the MR image (Adams stages 2, 3 and 4) (Adams et al., 2000). 
3. Decrease in the height of the disc space of more than 20% measured 
radiographically in lateral image. 
4. Absence of spinal infection. 
5. Hematological and biochemical analyzes without significant alterations that 
contraindicate intervention 
6. The patient is able to understand the nature of the study. 
7. Written informed consent of the patient. 
5.1.2 Exclusion criteria 
1. Age under 18 years old, or over 75 years old or legally dependent 
2. Allergies to gentamicin, or to bovine, bovine or equine sera. 
3. Congenital or acquired diseases with significant deformations of the spinal column 
that make application difficult. 
4. Vertebral pathology that conditions segmental instability, stenosis of the medullary 
canal, pathology of the isthmus and other alterations that could compromise the study 
at the discretion of the researchers 
5. Presence of Modic III changes in the RNM images (Modic & Ross, 2007) (Annex 
VIII). 
6. Weight overload with a body mass index (BMI) greater than 35 (obesity grade II; 
SEEDO), where BMI = mass in Kg / (height in m) 2 
7. Pregnancy or breastfeeding 
8. Neoplastic disease 
9. Immunosuppressive states 
10. Participation in another clinical trial or treatment with another product in phase 
Research in the 30 days prior to inclusion in the study. 
11. Any other pathology or circumstance that compromises participation in the study 
according to medical criteria 
5.2.1 Clinical Criterion 
It includes the evaluation of the state of health and quality of life through the SF-12 
questionnaire (abbreviated version of the SF-36), the evaluation of low back pain (and 
sciatic pain if any) using visual analog scale (VAS) and disability assessment using the 
index of Oswestry. They are described in detail in Annexes V, VI and VII. 
5.2.2 Imaging Criterion 
5.2.2.1 Radiography. 
The intervertebral space decrease of more than 20% in the profile projection in 
comparison with healthy adjacent segments is a criterion used for the purpose of 
inclusion or exclusion in the trial. 
The classification of degeneration by discographic criteria will be carried out according 
to the staging Adams (Adams et al., 1986): 
1. Cotton ball. No signs of degeneration 
2. Lobular. Nucleus pulposus amorphous, soft and white 
3. Irregular. Mature disc, with nucleus pulposus beginning to merge and with fibrous 
fragments 
4. Cracked. Degenerated disc, with fissures and cracks in the nucleus pulposus and in 
the inner part of the annulus fibrosus 
5. Broken. Degenerated disc, with radial fissure that reaches the outer edge of the 
annulus fibrosus 


                                         Disc_allo_MSV protocol. v.1.6 1                             16 
 
A lateral x-ray in standing and flexion-extension will be taken to assess the excess of 
mobility in the pathological segment and its evolution during treatment. 
5.2.2.2 Magnetic Resonance Imaging (MRI): 
T2 and STIR (short T1 inversion recovery) sequences will be performed in the axial 
and sagittal. They will be carried out at the beginning and 6 and 12 months after the 
intervention. It will be carried out quantification of the water content of the disc on the 
T2 image without contrast as described in detail in section 3.3 (see Figure 4). The MRI 
image will also be used to assess the integrity of the external fibrous ring at the 
inclusion visit. 
5.2.3 Laboratory Analysis 
They include serological determination of hepatitis B and C, HIV, lues and obtaining a 
sample of serum for seroteca. Although positive serology is not a criterion for exclusion 
of the recipient in this trial will be carried out for epidemiological purposes. The rest of 
the Analysis will be carried out according to usual protocols. Additional tests will be 
considered when clinical or complications are suspected radiographically. In the case 
of marrow donors 
It will be necessary to carry out HIV and hepatitis serology by PCR techniques (Nucleic 
Acid Amplification Technology, NAT) to maximize sensitivity and thus avoid quarantine 
which would otherwise be necessary (Roth, 2010), but impossible to fulfill in this case. 
This possibility is thus contemplated in RD 1301-2006 for cells and tissues. Would 
convenient, and so it has been programmed, to store a tube of serum, both from the 
donor and of the receiver, in the Seroteca to ensure the possibility of carrying out new 
analyzes before situations not contemplated or not known at the present time. 
5.2.4 Pathological study 
It will be carried out obligatorily in case of necessary subsequent intervention on the 
disc. 
5.3 SELECTION OF DONORS OF MESENCHYMAL CELLS 
Leftover cells from patients who undergoing autologous MSV transplantation in the trial 
Eudra CT2009-017405-11 that we are carrying out simultaneously or in compassionate 
cases authorized by the AEMPS which followed the same protocol.  In the above cases 
often we obtain more cells than needed for their own treatment in the selection process 
for adhesion to plastic. Informed consent will be requested (see Annex II) to donate 
part of the excess cells. Alternatively, if the above procedure is not possible, donors will 
be recruited among healthy patients undergoing spinal or hip surgery in the Service of 
Traumatology of the Hospital Clínico Universitario de Valladolid and who wish and 
consent to donate bone marrow obtained during surgery. Consent is shown reported in 
Annex II. 
 
5.3.1 Inclusion criteria: 
 Donors must meet all the criteria for the selection of blood donors and donation of 
hematopoietic precursors (RD 1088/2005, of September 16 by which establishes the 
technical requirements and minimum conditions of the hemo-donation and transfusion 
centers and services). 
 They must sign the informed consent. 
 They must undergo PCR serology (NAT) for HIV and hepatitis B and C and provide a 
serum sample for the seroteca (see details above). 
5.3.2. Exclusion criteria 
• Any criteria for non-compliance with the inclusion criteria 
• HIV or Hepatitis positive 
5.3.3 Procedure: 
It is described in detail below (section 6.1). In essence, in the Eudra CT2009-017405-
11 usually starts with 80-100 ml of bone marrow. The mononuclear cells and is 
selected by adherence to the plastic in T-175 bottles. Depending performance, which is 
highly variable depending on the patient, is obtained in this phase between 6 and 
45x106 adherent cells, which expand about 10 times in the following 3 weeks for use in 


                                         Disc_allo_MSV protocol. v.1.6 1                             17 
 
the clinical trial. Taking into account that the required number of MSV is of about 
80x106 cells, in some patients there is a significant surplus of cells in this stage. It is 
proposed here to start between 1 and 5 additional expansion batches (depending on 
the number of cells obtained) for use in the present clinical trial. The details of the 
protocol are discussed in section 6.1. 
5.4 NUMBER OF EXPECTED PATIENTS AND RATIONALE 
As it is a phase I-II study, in which the feasibility of the procedure is evaluated 
proposed and the safety of the product under study, the sample was fixed in 24 
patients (12 for each arm of the clinical trial). 
5.5 CRITERIA FOR NON-RESPONSE TO TREATMENT 
It will be considered that there is no response to treatment if 12 months after the 
intervention there is no significant clinical changes observed in the questionnaires and / 
or changes in MRI images showing signs of improvement in dehydration. Shall be 
deemed the partial response in case of evidence of clinical or regenerative 
improvement in isolated. 
5.6 CRITERIA FOR WITHDRAWAL OF PATIENTS AND PROCEDURES TO 
FOLLOW 
Patients can leave the study at any time, without having to give no explanation. 
Additionally, patients may be withdrawn from the study for the following reasons: 
1. They have adverse events that affect participation in the study 
2. They do not wish to continue (withdrawal of consent) for any reason. 
3. Violation of protocol or significant deviation from specific procedures 
of the study 
4. Loss of follow-up 
5. Appearance of a clinically significant intercurrent disease that affects the 
participation in the study. 
6. The investigator considers that it is beneficial for the patient to withdraw from the 
study. The withdrawal of the patient from the study will not represent for him any type 
of damage in the control of their disease, in subsequent treatments or in the treatment 
to be received by the doctor. If a patient is withdrawn from the study at any time the 
reason must be recorded in the corresponding sheet of the data collection notebook 
(CRD). Patients who are withdrawn from the study due to an adverse event or 
abnormal results of laboratory values should be followed up to total trial resolution or 
for a period of time considered clinically reasonable by the researcher. 
Patients withdrawn from the trial due to an adverse event will be included in security 
analysis. Patients who have undergone surgically intervened for graft insertion. 
If a patient is lost, an attempt should be made to contact him. The investigator it should 
reflect the loss of follow-up in the medical history. 
The aim of the study is to obtain 12 evaluable patients in each trial arm (24 in total). A 
patient will be considered evaluable as long as it has been infiltrated into the space 
intervertebral a dose of MSV or belongs to the control group. In the event that for some 
cause the application cannot be made to an included patient, another must be included 
patient in the same group until reaching the 12 patients treated in each arm of the 
clinical trial. The study exit and the causes of the study exit of the initial patient and no 
further follow-up will be necessary since they will not have received the 
Trial treatment. 
5.8 FOLLOW-UP OF PATIENTS 
The research team will inform all patients entering the study of the need to follow a 
specific periodic control and the importance of going to the planned visits. 
To patients who experience adverse events (regardless of whether they have dropped 
out or withdrawn from the study) will be followed until the incidence has subsided. 
resolved or stabilized at a level acceptable to both the coordinator and the promoter of 
the study. As it is a single administration, the option of withdrawal of the medication so 
it is expected that these patients can continue the follow-up provided in the protocol. 


                                         Disc_allo_MSV protocol. v.1.6 1                             18 
 
All patients included in the study who received cell therapy (including patients who 
have voluntarily left the study or are withdrawn from it) will continue regular check-ups 
after participation in the study. These controls will be carried out in the Orthopedic 
Surgery and Traumatology Service of the Hospital Clínico Universitario de Valladolid 
with a frequency not less than once a year. These controls should include a clinical 
evaluation, an X-ray and a general analysis (acceptable if they have been carried out 
up to 3 months before the visit). The follow-up will be done with a minimum of 5 years. 
In case that any relevant information was detected for the study related to both the 
efficacy of the product as well as the safety of the subject (and attributable to the 
therapy received) is will notify the promoter, initially by telephone and, if deemed 
appropriate, facilitating  supporting documentation (signed report or adverse event form 
serious) by fax or email. 
In addition, and as indicated in the next point, to all patients who have received 
medication in the study will be given a Participation Card. At this time The research 
team will ask them that, in case of presenting a health problem relevant inform the 
doctor who attends you about your participation in said trial clinician by presenting said 
card. Particular attention will be paid to possibility of histological study if at any time a 
surgical technique is practiced on the treated area. This follow-up is not required for 
control patients. 
5.9. STUDY PARTICIPATION CARD 
All patients who have received the study medication will be given a identification 
tracking card so that, if necessary, you can contact the research team. This card will 
have a DNI size so that it can always be carried in the patient's portfolio and will 
contain the following text: 
IDENTIFICATION CARD: 
The holder of this card, Mr / Mrs: _______________________________ is participating 
or you have participated in a clinical trial of cell therapy in which you received treatment 
with allogeneic mesenchymal cells (Protocol code: Disc_allo_MSV). Saying treatment 
was administered on the day: _____________ and corresponds to the number of 
Serie__________ If you or your doctor need additional information about the study or 
the treatment, or report an incident, please contact: 
Principal investigator: _____________________________ 
Telephone contact: ______________________________ 
Service: _________________________________________ 
Center: __________________________________________ 
If it is not possible to contact the Principal Investigator, please contact with the Spanish 
Agency for Medicines and Health Products (C / Campezo, 1, Parque Las Mercedes 
Business, 28022 Madrid. Tel: 91 822 6073) 
5.10 TEST DURATION 
The trial will last 12 months after treating all the 24 included patients (12 in each trial 
arm). 
6. TREATMENT AND STUDY PROCEDURES 
6.1 IMP AND REFERENCE THERAPY 
The product or drug under study is, in the control arm, the usual treatment based on of 
rehabilitation physiotherapy, postural hygiene and pharmacotherapy together with the 
injection of 2 ml 1% mepivacaine (obtained by mixing 1 ml of 2% mepivacaine with 1 ml 
of serum physiological saline) in the area of the paravertebral muscles close to the 
affected segment, using the same maneuvers as in the intervention in the experimental 
arm. (see section 2.4). In the experimental arm, the investigational drug or product is 
MSV, which are bone marrow mesenchymal cells processed according to the IBGM 
system from Valladolid, suspended in isotonic Ringer-lactate medium with human 
albumin at 0.5% and 5 mM glucose. Cell dose: 25x106 ± 5x106 MSV, in a volume of 2 
ml of cell suspension. Stability demonstrated is> 12 hours at 4-20 ºC. The whole 
process of obtaining MSV is carried out by highly qualified specialists in crops cell 
phones and is developed in the Cell Production Unit of Citospin (Parque Científico de 


                                         Disc_allo_MSV protocol. v.1.6 1                             19 
 
la UVa), meeting GMP criteria and following protocols approved by the AEMPS (PEI 
No. 10-134). 
In the validations carried out, MSV has been shown to possess the characteristics 
typical MSC defined by the Society for Cellular Therapy (Dominici et al., 2006): 1) 
Adherence to plastic in cultivation; 2) Expression of CD73, CD90 and CD105 antigens. 
3) Absence of hematopoietic antigens, markers of monocytes, macrophages and B 
lymphocytes. 
4) In vitro differentiation capacity in osteoblasts, adipocytes and chondrocytes. Watch 
details in Figures 2 and 3. 
6.1.1. Obtaining, cultivating and expanding MSV. 
The processing and multiplication of harvested bone marrow cells using the IBGM 
procedure will last 3-4 weeks. The responsible medical team is expert in the 
management of the selection, culture and collection procedure of the cell product that, 
in its status available for application, is called MSV (the V added to the initials usual 
ones comes from Valladolid, to indicate that it follows the procedure developed, 
validated and authorized in our Cell Production Unit)). 
As a cellular source for obtaining MSV, bone marrow aspirate is used from healthy 
donors submitted to the protocolized anticoagulant procedure. The protocol of 
obtaining is described in sections 5.3 and 6.1.6 and the consent documentation 
reported is included in Annex II. Once the bone marrow sample has been received (in a 
period less than 12 hours) and after checking the perfect condition of the shipment and 
the correct Completion of the accompanying documentation (informed consent of the 
donation, serologies, NAT etc), the bone marrow processing will be carried out in the 
Citospin facilities, in the Science Park of the University of Valladolid. In essence, the 
mononuclear cells are separated from the bone marrow aspirate by density gradient 
with Ficoll and subsequently a feasibility study is carried out mobile. During cultivation * 
2 trypsinization processes or passes will be carried out, which have as an objective 
multiplying and purifying the cell line. In order to ensure that cells in culture are really 
MSV and the achievement of the established dose, the culture of will last for 3-4 
weeks, until you have a sufficient number of cells (25x106 cells / intervened segment). 
The details of the specifications are those that appear in Production Guide (Preparation 
of Cell Therapy: expansion of mesenchymal cells bone marrow: FA-CMES-001-P). 
Serum samples will also be obtained from donor to carry out the mandatory serologies 
(RD 1301-2006, for cells and tissues human), performed using the PCR technique 
(NAT by Nucleic Acid Technology) to avoiding quarantine (Roth, 2010) and keeping a 
sufficient sample in the seroteca to further analysis, if necessary. 
It has recently been conclusively shown that, contrary to what is stated in previous 
publications, there is no malignancy or genetic alterations in SCD maintained and 
expanded in vitro for prolonged periods (Bernardo et al., 2007; Bernardo et al., 2009; 
Bernardo et al., 2011), and that the initial errors were due to contamination with other 
immortalized cell lines grown in the same laboratory (de la Fuente et al., 2010; Torsvik 
et al., 2010; Vogel, 2010). At the end of the process, the characterization of the MSV 
will be carried out through studies immunophenotypic using flow cytometry, using the 
markers established for this type of cells, a higher positive cell phenotype should result 
(> 95%) for CD73, CD105, CD90, CD166 and negative (<10%) for CD45, CD14, CD34, 
CD31 and HLA-DR. 
The cells will be packed in 5 ml syringes suspended in 2 ml of isotonic solution. Ringer-
lactate, supplemented with human albumin (0.5%) and glucose (5mM). The number of 
cells administered will be 25 ± 5x106 cells. The sterility, cleanliness and quality control 
conditions of the production unit will be maintained following the steps defined in the 
Standard Procedures for Work established by the GMP norms of the "Cell Therapy Unit 
of the IBGM". 
6.1.2. Conditioning and transport for shipment. 
Once the MSVs are obtained, they will be resuspended in 2 ml of Ringer-lactate 
isotonic medium, supplemented with human albumin (0.5%) and glucose (5mM) to be 


                                         Disc_allo_MSV protocol. v.1.6 1                             20 
 
loaded into a 5 ml labeled syringe. This product has a stability of more than 12 hours at 
room temperature according to our protocol. The medicine will be transported in 
refrigerators validated for such activity, keeping it between 4 and 16 oC. 
It has been found that, in these conditions, it fully retains viability for> 12 hours (Orozco 
et al., 
2011). 
6.1.3. Cell application. 
Antibiotic prophylaxis will be performed with 2 g of IV cefazolin or 1 g of IV vancomycin 
in case allergy. The implantation of the cells is carried out under light sedation and 
radiological control. The cells are injected by puncture of the disc avoiding the 
neurovascular elements (Konings & Veldhuizen, 1988). After double brushing the 
region with a aqueous solution of povidone iodine (or chlorhexidine in patients allergic 
to iodine), The field is delimited with sterile sheets and local anesthesia (Scandicain 
1%) is applied to the skin, subcutaneous tissue and muscle near the puncture. With 
fluoroscopy in position anteroposterior, a vertical line is marked on the skin 
corresponding to the projection of the spinous process with a sterile dermographic 
pencil. Then a line is drawn perpendicular corresponding to the projected image of an 
aligned Kirschner wire with the intervertebral space to be treated and a 20G spinal 
needle is inserted with an inclination 25 to 35 degrees toward the midline at a point 8 to 
9 cm (depending on the patient morphotype) from the midline. At this time, fluoroscopy 
is switched to lateral position to ensure needle penetration follows the correct direction 
until the nucleus pulposus is reached. After verifying the correct position of the needle 
in the nucleus pulposus both in the anteroposterior fluoroscopic view and in the side, 
the cell suspension is slowly injected. Using this procedure, do not we had incidents in 
none of the 10 patients in our previous study (Orozco et al., 2011). 
6.1.4 Post-treatment regime 
The patient is discharged after a 2-hour observation period. Not prescribed Lumbostat 
corset and walking is allowed for moderate periods. Activity is suspended work for a 
week. Exercises to tone the muscles are prescribed para-vertebral and abdominal, 
which begin one month after the intervention. Medication analgesic is adapted to the 
needs of each patient and use should be avoided as far as possible of anti-
inflammatories. Long-term follow-up will consist of clinical visits and monitoring 
Radiographic and MRI as specified in point 7.2 (“Schedule”). 
6.1.5. Possible complications derived from the proposed therapy. 
The complications are the same as in the discography, and they occur very rarely. The 
most common complaint is exacerbation of pain for 1-2 weeks, which usually resolved 
by analgesia and muscle relaxants for a period short. The most serious complication is 
discitis, the incidence of which is less than 0.1% (Osti et al., 1990). Other complications 
described, although much less frequently, are transient headache, nausea, meningitis, 
epidural abscess, arachnoiditis, bruising intrathecal, retroperitoneal hematoma, cauda 
equina syndrome and acute disc herniation. Isolated cases of urticaria are not 
considered in this trial, as they are attributable to contrast medium. Initial fears about 
possible side effects of the Long-term discography regarding disc viability have not 
been confirmed. In a study with up to 20 years of clinical follow-up, no radiographic 
evidence was found of progressive disc degeneration after discography (Flanagan & 
Chung, 1986). The possible risk of complications derived from the use of allogeneic 
cells has been discussed in detail above. Suffice now to summarize that, according to 
the literature, the application of Allogeneic MSCs, both locally and systemically, have 
been shown to be safe both in the context of clinical trials and studies in animal 
models. Either way, will monitor skin and mucosal reactivity to watch for a possible 
immune reaction. 
6.1.6. Methodology for obtaining bone marrow from donors. 
This procedure will be applied to donors, generally included in the Eudra trial. CT2009-
017405-11 (MSV_Artro) that we are carrying out or in compassionate cases authorized 


                                         Disc_allo_MSV protocol. v.1.6 1                             21 
 
by the AEMPS, and that follow the same protocol and that provide their cells left over 
for this test (see section 5.3). 
The methodological protocol will be the one described in MSV_Arto: Marrow puncture-
aspiration bone will be performed in the outpatient surgery operating room in a 
scheduled session. The patient in the prone position, accommodated with pillows, will 
undergo mild sedation. Then the surgical field will be brushed with alcoholic povidone-
iodine solution (chlorhexidine if there is a history of allergy to iodine) and delimitation 
with sterile fields leaving both posterior iliac crests free. After local anesthesia (10 cc + 
10 cc of 1% lidocaine, without vasoconstrictor) and sedation, two members of the 
extraction team, located at both sides of the operating table, with a 11 G trocar, various 
punctures located under the posterior superior iliac spine towards the joint sacroiliac 
(this is the area of the iliac with the highest trabecular density). The technique involves 
the Cortical perforation and sudden aspiration of a maximum of 1mL of bone marrow to 
avoid in peripheral blood aspiration is possible. The material obtained is injected into 
the bag supplied for transport that has previously been heparinized with an adequate 
dose to blood volume. The 2 successive aspirations are carried out by rotating 90º in 
the direction of the beveled trocar clockwise. The same puncture hole allows 1-2 depth 
mm about two times, repeating the same 1 mL aspiration methodology, change of 
syringe, 90º bevel rotation and new aspiration. The trocar can then be removed slightly 
and by sliding it a few millimeters over the cortex of the pelvis, the puncture, continuing 
on both sides of the pelvis until about 80 mL is achieved. immediately transport the 
marrow (sterile heparinized bag with a medium volume of 80 mL of aspirated bone 
marrow) to the Citospín Cell Therapy Unit, Parque UV scientist, under regulated 
conditions and room temperature (15 to 25 ºC) in a maximum of 12 h. 
6.2. TREATMENT ASSIGNMENT 
6.2.1. Numerical correspondence of patients 
The patients will be identified with a correlative number until the inclusion of the 24 
patients (example: 001, 002, etc). In the event that an initially enrolled patient is need 
to be replaced, the assigned number would be the same one preceded by an R 
(example: R01, R02, etc). 
6.2.2. Randomization numbers 
The study population will be made up of 24 patients with low back pain attributable to 
degenerative disc disease that is refractory to conventional treatment and with integrity 
of the external annulus fibrosus demonstrated by MR imaging. Of this cohort, 12 
patients will be included in the experimental group and another 12 in the control group. 
Will be assigned to one or the other randomly. It will be carried out by the CRO 
centrally and at random, attending to the treatment to be administered to each patient 
(control or experimental). The assignment will be kept in a sealed and identified 
envelope. 
6.3. CONCOMITANT TREATMENTS 
Relevant concomitant medications taken by the patient will be recorded in the CRD 
regularly due to other parallel treatments allowed during the study. If analgesic 
treatment is necessary, it will preferably be carried out with paracetamol. I know avoid 
administering corticosteroids or anti-inflammatory therapy if they are not strictly 
necessary. If necessary, it should be noted in the clinical history and in the CRD 
(Section "Concomitant Medication"). 
6.4. ACCOUNTING OF THE DRUG 
The product under study or medicine is produced individually by starting from the bone 
marrow from each donor. In all cases, the MSV will be registered and identified. 
produced for each patient in the IBGM. 
6.5. MANAGEMENT OF STUDY MEDICATION 
The study medication, properly packaged MSV in a thermostatic container, was 
transported immediately after production to the application center. Has a stability longer 
than 12 hours at room temperature and is given as an injection in the area of the 
nucleus pulposus of the affected spinal segment. 


                                         Disc_allo_MSV protocol. v.1.6 1                             22 
 
 
7. DEVELOPMENT OF THE TEST AND ASSESSMENT OF THE RESPONSE 
7.1 ASSESSMENT OF THE RESPONSE 
7.1.1. Main evaluation variable 
The objective is the evaluation of the efficacy using clinical criteria (Visual evaluation 
back pain analogue-VAS-, Oswestry disability index -ODI-, quality of life --SF-12--), and 
imaging (quantitative MRI) at 6 and 12 months after intervention. 
7.1.2. Secondary evaluation variable 
There are no secondary variables for efficacy. 
7.2 TEST SCHEDULE 
 
 
VER TABLA EN LA PAGINA SIGUIENTE 
 
 
 
* Las MSV deben haberse obtenido del donante y expandido en la ventana temporal 
adecuada. **RX en quirófano para guiar y seguir aplicación. La RM de Vo se usará 
también 
para valorar la integridad del anillo fibroso externo. 
 
CRONOGRAMA 
Preinclusión 
Inclusión 
Tratamiento 
Seguimiento (m=meses) 
PROGRAMA 
DE VISITAS: 
V0 
Día 1 
V1 
Día 8 
V2 
3 m 
V3 
6 m 
V4 
12 m 
V5 
Historia Clínica y 
Exploración Física 
X 
X 
X 
X 
X 
X 
Entrega de la Hoja de 
Información 
X 
RX Columna Lumbar 
Simple y dinámica 
X 
X 
X 
Firma del Consentimiento 
Informado 
X 
Serologías víricas 
preceptivas 
X 
Comprobación de criterios 
de Inclusión y Exclusión 
X 
RM lateral, T2, cuantitativa 
X 
X 
X 
EVA, Oswestry, SF-12 
X 
X 
X 
X 
Tratamiento control o con 
MSV alogénicas* 
**X 
Analítica Control 
X 
X 
X 
X 
VISITA: 
0 
V1 
V2 
V3 
V4 
M 
V5 
12 M 


                                         Disc_allo_MSV protocol. v.1.6 1                             23 
 
 
7.2.1. Visiting Program 
Pre-Inclusion: In patients who come for consultation and whose medical history and 
examinations complementary, including X-rays and / or MRI, presume an orientation 
diagnosis with the possibility of inclusion in the trial, presenting all the criteria of 
inclusion and none of exclusion, the treatment regimen will be prescribed according to 
the standard and then they will be informed of the possibility of inclusion in the EC. 
They will deliver the "Patient Information Sheet" (Annex II) and, if its decision is 
affirmative, Inclusion procedures will begin on a future visit. 
Visit 0. Inclusion. May comprise more than one physical visit. If the patient confirms 
that want to join the trial, you will be asked to sign the “Consent Document Informed 
”(Annex II). You will be ordered new MRI and radiographic scans with the mandatory 
characteristics of the study unless these examinations had already been performed 
previously within a period of no more than 6 months. Completed analytics will be 
requested with the regulated serology for determination of HIV, Hepatitis and Lúes and 
test of pregnancy if you are a woman of childbearing age. Although positive serology is 
not a reason for exclusion in this trial, it will be done for epidemiological reasons. After 
checking the inclusion and exclusion criteria, the clinical history will be made, including 
data referring to low back pain and discopathy, treatments carried out, analytics and 
imaging tests to define the characteristics of the same and carry out the measurements 
that will be taken as a standard of future explorations. Low back pain evaluation 
questionnaires will be passed (VAS), disability (Oswestry) and quality of life (SF-12). It 
will be scheduled on the day of the intervention (V1) and the X-ray and MRI tests will 
be performed, if they had not already been performed.  
Visit 1 (day 1). Placebo injection or allogeneic MSV, depending on the clinical trial arm. 
Visit 2 (8 days): Safety assessment. Includes analytical control. 
Visit 3 (3 months): Safety assessment. EVA, Oswestry and SF-12 questionnaires. RX. 
Visit 4 (6 months): Safety assessment. EVA, Oswestry and SF-12 questionnaires. RX. 
RM. 
Visit 5 (12 months) Safety assessment. EVA, Oswestry and SF-12 questionnaires. RX. 
RM. 
8. ADVERSE EVENTS (AA) 
8.1. Definition 
Adverse event is any unfavorable medical event that occurs in a patient or subject 
undergoing clinical investigation who is administered a product Pharmaceutical, 
regardless of whether or not it is considered related to the product pharmacist. Any 
sign (including alteration of a laboratory parameter), symptom or disease, unfavorable 
and unintended, that appears associated temporarily with the use of a medicinal 
product can constitute an event adverse. 
Unexpected adverse events are those experiences not described (in nature, severity or 
frequency) in the technical data sheet of the product.  
8.2 Description of adverse events 
Previous publications have shown that the interventions proposed in this rehearsal are 
safe. Our preliminary clinical experiences with autologous MSV and in General MSC 
have not identified any Adverse Health or Safety Event caused or associated with 
them. 
Possible risks related to sedation combined with necessary local anesthesia for bone 
marrow aspiration in the MSV donor group are: hypoxemia, arrest respiratory, 
aspiration pneumonia, hypotension and death. However the probability of a 
complication of this severity should be considered exceptional. 
Possible risks related to donor bone marrow aspiration are: 
 Minimal bleeding from a puncture site; minor complication, only requires a 
compression bandage. 
 Feeling of nausea and instability in the hours following sedation. By This reason is 
usually kept in hospital for the next 2 hours to obtaining. 


                                         Disc_allo_MSV protocol. v.1.6 1                             24 
 
 An allergic reaction to any of the anesthetic drugs used is considered an exceptional 
complication, with an incidence of less than 1 in 50,000 anesthesia. 
 Fever, sometimes a few tenths in the first hours after obtaining. 
 Pain in the puncture sites that is quickly controlled with pain relievers common, 
paracetamol type, and usually disappears in less than 48 hours. To promote its 
resolution, it is recommended to take a few days of relative rest.  
Interventions carried out during treatment (local injection of mepivacaine or Allogeneic 
MSV) derived from product infiltration are minor, and attributable to the diagnostic 
recording technique, namely, the risk associated with the sedation, possibility of 
infection or bruising, death. However, it is understood that the treatment proposed in 
this study does not imply risks greater than those of surgery habitual of the 
contemplated pathology. Rather, it involves avoiding a technique open surgical 
procedure and the implantation technique is the same as that used in the discography, 
a widely used and widely used diagnostic technique experience. Sedation and local 
anesthesia are assumed to maintain very high risk levels. low under conditions of good 
clinical practice Aside from local pain or swelling, the arm of allogeneic MSV may have 
theoretically immunological rejection, although, as detailed in another section, MSCs 
have little or no antigenic power and this type of phenomenon has not been described 
or in animal experiments (rabbit and pig) or in clinical trials conducted in patients with 
lupus erythematosus ((Sun et al., 2009; Liang et al., 2010).have obtained similar 
results with allogeneic mesenchymal cells derived from cord blood (Sun et al., 2010) 
There are also numerous treated cases of patients with breast cancer (Koc et al., 2000) 
graft versus host disease (Lazarus et al., 2005), and other autoimmune diseases 
(Bernardo et al., 2009; Bernardo et al., 2011) without that there have been, so far, 
adverse effects. Finally, there are 44 declared trials clinicians using allogeneic MSCs in 
the “clinicaltrials.gov” database for treatment of very varied pathologies, including not 
only graft-versus-host disease and different autoimmune diseases, but also ischemic 
strokes, cardiac or peripheral disorders, liver destruction, osteogenesis imperfecta or 
degeneration of the intervertebral disc (see 
http://clinicaltrials.gov/ct2/results?term=mesenchymal+allogenic). On summary, both 
animal experimentation and use in human clinical trials demonstrates the safety of 
allogeneic mesenchymal cells, without having reported adverse effects. The collection 
of Adverse Events must be carried out by the researcher responsible for the trial, 
describing it according to its duration, intensity, frequency and relationship of causality 
between the treatment and the adverse event. The researcher should ask indirect 
questions directed to the patient at each visit of the study. Adverse events can also be 
reported voluntarily by the patient during or between visits or detected in physical 
examinations, laboratory tests or in other evaluations. In the Data Collection Notebook 
(CRD) of the study, the researcher must record in reference to A: A. Duration: refers to 
the time elapsed since the occurrence of the event until completion. 
B. Intensity: it will be defined according to a scale of three gradations: 
 mild: does not interfere with the subject's daily life 
 moderate: interferes but does not impede normal activity. 
 severe: interferes with some important aspect of daily life and can even force to 
abandon the treatment. 
C. The frequency: it will be defined as: punctual, recurring or persistent. 
D. The causal relationship: it will be established according to the classification in which 
the following categories: 
 Not related 
 Unlikely 
 Possible 
 Probable 
 True 
8.3 Record of Adverse Events 


                                         Disc_allo_MSV protocol. v.1.6 1                             25 
 
Adverse events observed during the clinical trial, either either by the researcher or by 
the patient himself, they must be recorded in the description of adverse events. This 
form can be found in the CRD of each participant in the study. 
Adverse Events will be recorded from the moment the patient signs informed consent. 
All of them will be logged, regardless of the relationship of imputed causality. 
8.4 Serious Adverse Event (AAG) 
8.1.4.1 Definition 
A Serious Adverse Event is any unfavorable medical event that any dosage of the 
product or due to specific study procedures: 
 Produces the death of the patient, 
 Threatens life, 
 Produces permanent or significant disability, 
 It gives rise to hospitalization or prolongation of it, (hospitalizations scheduled prior to 
patient selection or study procedures, will not be considered AAG). 
 Congenital anomalies and malignant processes. 
8.1.4.2 Notification of Serious Adverse Events (AAG) 
The investigator is responsible for the immediate reporting of adverse events. serious 
or unexpected. The investigator must notify any AAG to the CRO (FTH) in the within 
one working day from the moment the investigator learns of the existence of the 
serious or unexpected adverse event, regardless of the causal relationship. 
The minimum information that an initial report of a serious adverse event must collect 
(It can be notified by phone, fax or via email) is: 
 name of the researcher, 
 protocol code, 
 study drug, 
 patient identification number, 
 description of the event, 
 start date, 
 severity criteria and 
 causality of the event 
The investigator should send the trial monitor within 24 hours of the When you become 
aware of an AAG, the Notification of AAGs form (Annex IV) completed, signed, dated 
and with all the information available at the time. 
In the event that the AAG or unexpected has caused the death of the subject or placed 
in 
danger to his life, the investigator will contact the trial monitor and send the form 
Serious Adverse Event Notification Form completed and signed and dated on the 
within 24 hours from the moment the researcher becomes aware of the same. 
The CRO (FTH) will act on behalf of the Promoter to notify the AEMPS, the CEIC that 
is applicable and the competent bodies of the applicable Autonomous Communities, 
the suspicions of serious and unexpected adverse reactions that may be related to the 
investigational drug. Likewise, all the participating researchers. 
Unexpected causal related AAGs will not be notified to the competent authorities with 
other procedures of routine clinical practice in the treatment of these pathologies, 
particularly those of surgical procedures. Expected serious adverse events, non-
serious adverse events and those that are considered unrelated to the treatments 
under study will be included in a tabulated in the annual or final report of the clinical 
trial. 
9. ETHICAL ASPECTS 
9.1 ETHICAL AND REGULATORY REQUIREMENTS 
The study will be carried out in accordance with the protocol, the ethical principles 
based on the latest version of the Declaration of Helsinki (WORLD MEDICAL 
ASSOCIATION DECLARATION OF HELSINKI. (Ethical Principles for Medical 
Research Involving Human Subjects) (Annex III), in the Guidelines of the International 
Conference on Harmonization (ICH) on Good Clinical Practice (ICH Topic E: Good 


                                         Disc_allo_MSV protocol. v.1.6 1                             26 
 
Clinical Practice. Note for Guidance on Good Clinical Practice. CPMP / ICH / 135/95 
and to any new version or modification existing; as well as applicable national and / or 
international legislation. 
9.1.1 Investigator Responsibilities 
Before starting the study, the Investigator must sign a protocol signature page 
confirming that you agree to carry out the study in accordance with these documents 
and with all the instructions and procedures described in the protocol and that, when 
required, will allow designated monitors, representatives of the Warranty Department of 
Clinical Quality (CQA) and the Health Authorities have access to all the data and 
relevant records. 
The Investigator is responsible for providing patients and / or their representatives with 
adequate oral and written information about the study. All questions about the study 
must be answered to the patient and / or their legal representatives. 
9.1.2 Informed Consent 
Eligible patients can only be included in the study after providing for written informed 
consent previously approved by the CEIC (Annex II), or, in the case of inability to do 
so, after said consent has been granted by a legal representative of the patient, or in 
the event that he lacks a legal representative the person linked to the patient for family 
reasons. Informed consent must be signed and dated by the patient and the 
investigator, who will have provided each patient (or a representative of the patient) 
prior to inclusion in the study, information complete and adequate verbal and written 
study objectives and procedures, as well as as the possible risks that it may entail. The 
bone marrow donor will thus receive himself, an information sheet and will sign a 
consent authorizing the use of his cells for allogeneic transplantation (see Annex II). 
Informed consent must be obtained before starting any procedure. study specific (i.e. 
all procedures described in the protocol). The process of obtaining informed consent 
must be recorded in the documents patient source. 
The proposed informed consent forms are provided in ANNEX II. that meets regulatory 
requirements and is deemed appropriate for this study. The informed consent / patient 
information sheet includes the items listed in the ICH Guideline on Good Clinical 
Practice. Any change in the Informed consent proposed by the investigator must be 
approved by the Promoter and notified to the corresponding CEIC. 
9.1.3 Approval of the Clinical Research Ethics Committee (CEIC) 
 Before starting the study, the written, signed and dated approval of the protocol, 
informed consent and patient information sheet by the CEIC applicable according to 
current national legislation. The approval must be saved in the file of the researcher in 
the center and a copy in the file of the Promoter. 
9.1.4 Approval of the Health Authorities 
Before starting the study, all established regulatory requirements must be met and the 
clinical trial must be approved. The Promoter or representative of the Promoter 
together with the Researcher will request the approval of the Health Authorities. This 
approval is will be kept in the Researcher's file at the study center, with a copy in the 
file of the Promoter. 
9.2 MODIFICATIONS OF THE PROTOCOL 
Any changes or additions to this protocol can only be made through a Written 
amendment to the protocol, which must be approved by the AEMPS and CEIC 
corresponding, when required according to current applicable legislation. All 
amendments to the study protocol will be made in writing and filed in the corresponding 
study file, as a modification of the protocol. Are Modifications must be documented, 
dated and signed by the investigator and the Promoter. 
9.3 INSURANCE POLICY 
The promoter of the study, will arrange an insurance that covers the damages and 
losses that as a consequence of the same could result for the person in which it is to 
be carried out: Said civil liability insurance will cover the responsibilities of the 
Promoter, the researcher and his collaborators and the head of the hospital or center 


                                         Disc_allo_MSV protocol. v.1.6 1                             27 
 
where the trial is carried out and will comply with current applicable legislation. Policy is 
attached. 
9.4 ACCESS TO PATIENT DATA 
The patient's medical information obtained by conducting this study is considered 
confidential and its disclosure to third parties is prohibited. The confidentiality of the 
patient is insured since they will be identified only by their initials and a code number of 
the assigned study. 
The investigator will inform patients that their identity will be strictly maintained 
confidential. During the study, the patient will be guaranteed strict compliance with the 
Law 15/1999 of December 13, Protection of Personal Data. The researcher, when 
processing and treating the patient's data, will take the necessary measures 
appropriate to protect them and prevent access to them by unauthorized third parties. 
The patient may revoke the informed consent for the processing of their data personal, 
addressing the investigator. 
The data generated as a result of the clinical trial must be available to be inspected at 
the request of the Promoter, the CEIC or the Health Authorities. The signing of the 
informed consent means that the patients explicitly accept that the study data may be 
consulted by the researcher and his team, the representatives of the Promoter and if 
required by the CEIC and Health Authorities. 
 
10. PRACTICAL CONSIDERATIONS 
10.1 RESPONSIBILITIES OF THE VARIOUS PARTICIPANTS IN THE TRIAL 
10.1.1 Investigator 
The researcher must comply with all the requirements of the protocol, he will be 
responsible for the information is accurate and truthful and has been obtained in the 
manner indicated therein. In particular, the investigator must ensure the best possible 
care at all times. of the patient always putting their safety and well-being first. 
10.1.2 Monitor 
The monitor must confirm that the information collected in the CRD is true, for which 
must have the collaboration of the research team. In addition, you will be responsible 
for communicate to the Sponsor any serious or unexpected adverse events that occur 
during the study. 
10.1.3 Promoter 
The Promoter will be responsible for ensuring compliance with the ICH Directive on 
Good Clinical Practice and applicable national and / or international regulations. 
10.2 DATA REVIEW 
10.2.1 Center monitoring 
Before starting the study, a meeting of the monitor will be held with all the investigators 
and the protocol and the correct composition of the CRDs will be reviewed. During the 
study, the monitor designated for the test will regularly visit the entrance to check that 
patient documents are complete, data accuracy of the CRDs, the monitoring of the 
Standards of Good Clinical Practice (GCP) and the progress of recruitment. 
Investigators and all personnel involved in the trial should be available to assist the 
monitor during these visits. 
The researcher must make available to the monitor the source documents of each 
study patient that will consist of the history and notes of the visit (medical records, 
clinical or hospital) including medical and demographic information, data from 
laboratory and the results of any other tests or evaluations. All the information that is 
registered in the CRDs, it must be verifiable with the source documents that they are 
usually found in the patient's medical record. The investigator must keep a copy of the 
signed informed consent form. 
The researcher must agree to the monitor reviewing all source documents for confirm 
that the data is consistent with the data in the CRDs. A complete verification of the 
existence and correct obtaining of informed consent, of the compliance with the 
inclusion / exclusion criteria, the documentation of the AAGs and the record of the data 


                                         Disc_allo_MSV protocol. v.1.6 1                             28 
 
used for all efficacy and safety variables. I know carry out additional checks of the 
consistency of the original data with 
those of the CRDs, according to the study's specific monitoring plan.  
10.3 DATA COLLECTION 
10.3.1 Data collection notebook (CRD) 
All the data generated in the clinical part of this study will be transcribed in the CRDs 
they will be printed in triplicate (carbonless paper). All data will be transcribed and 
modifications will be made in black ink. Any correction of the data must be signed, 
dated and with the reason for the modification noted. Only authorized personnel can 
enter data and make corrections in the CRD. The Investigator and study monitor will 
review all CRDs to ensure they are complete and legible and accurate. The monitor will 
instruct the center staff to make any necessary corrections or additions. The study 
monitor will have access to the medical records, original laboratory data and other 
related documents with the study, without compromising the identity of the patients. 
CRDs should be completed on a regular basis to keep data up to date and reflect the 
patient's condition in each period of the trial. The information collected and entered in 
the CRD will correspond to that of the source documents. 
Patients will not be identified by name on the CRD, an ID will be used coded consisting 
of a patient number and initials. The researcher must carry out a confidential record 
(patient identification list) containing information about identification of the patient 
included in the trial in order to keep track of the themselves if necessary. 
10.3.2 Original data 
The original data are those that provide evidence of the existence of the patient and 
they ensure the integrity of the data collected. All data on the patient's participation in 
the study and clinical status during the period of the study should be noted / filed in the 
patient's medical record. This data is defined as original data. Medical information 
relevant to the efficacy and safety evaluation will be transcribed to specifically designed 
CRDs for the study and also collected in the clinical history. During monitoring visits, 
consistency between stories will be checked patient clinics and CRDs, that is, 
verification of original data (SDV). 
These, in case there is any discrepancy, must be justified. 
10.4 DATA CONSERVATION AND RECORD KEEPING 
All data related to the study, including the contents of the file of the study, CRDs and 
original data will be stored by the researcher for a period at least 15 years old. The 
investigator will keep a copy of each CRD and the original will be kept will send to the 
Promoter. 
The investigator's file will contain the documents described in the ICH Directive on 
Good Clinical Practices.  
The clinical records of the patients and other original data will be kept as much as 
possible period of time allowed by the hospital, institution or private practice where the 
performed the test. The Promoter will keep all the remaining documentation related to 
the trial during the period validity of the drug. 
10.5 QUALITY CONTROL 
During the development of the trial, monitoring visits will be carried out periodically  to 
the centers to ensure that the protocol requirements are followed. 
10.6 INSPECTIONS AND AUDITS 
The Promoter, either directly or through contracted third parties, may carry out quality 
assurance audits at participating centers. In the event of audits, the auditor will have 
access to medical records, files and relevant documentation related to the clinical trial. 
Health Authorities may carry out inspections during the study and after its ending. In 
the case of audits and / or inspections, the researcher will provide all the 
documentation related to the study. 
10.7 PRESENTATION AND PUBLICATION 
All information regarding this clinical trial is considered strictly confidential and is the 
property of the Sponsor, who may use the Study data for scientific or commercial. Any 


                                         Disc_allo_MSV protocol. v.1.6 1                             29 
 
information related to the study will not be communicated to third parties without the 
prior written authorization of the Promoter. 
The publication or presentation, whether complete or partial, of any part of the data or 
Trial results will be subject to review and written agreement with the Promoter. 
11. STATISTICAL ANALYSIS 
11.1 SAMPLE SIZE 
As it is a phase I-II study, in which the safety of the product under study is evaluated, 
the sample was fixed at 12 patients per branch (24 patients in total) 
11.2 STATISTICAL METHOD USED 
In all descriptive analyzes, categorical variables will be summarized using frequencies 
and category percentages. For the distributions of continuous variables, will present the 
mean and its Standard Deviation, the median and the 25th and 75th percentiles of the 
distribution, the number of cases, minimum and maximum value. 
All hypothesis tests will be two-tailed, with a significance level of 5%. The The result of 
a hypothesis test will comprise the 95% Confidence Interval of the variable (s) 
analyzed. To calculate the statistical significance of the differences between the two 
groups, a normality analysis of the distribution will be carried out and compare the 
means using the double-tailed t-test or the Wilcoxon, depending on whether the 
population is Gaussian or not. 
11.2.1 Main objectives, main variables 
- Evaluate the feasibility and safety of the use of allogeneic MSV injected into the disc 
space for the treatment of lumbar degenerative disc disease and pain and the disability 
it causes. 
The variables that will be used to evaluate safety will be the AAG number related to 
study medication and the percentage of patients who presented a related AGS. 
-Evaluate the analgesic-anti-inflammatory efficacy determined by the variation of the 
Low back pain assessment questionnaire scores (VAS), disability (Oswestry) and 
health and quality of life (SF12) at 3, 6 and 12 months. 
- Evaluate regenerative efficacy using quantitative MRI imaging criteria determined by 
the appearance of improvements in disc dehydration at 6 and 12 months. 
11.2.1.1 Radiographic criteria 
Adams stage 2-4 classification (Adams et al., 1986), with (fibrous ring capable of 
contain the cell implant), used for inclusion or exclusion purposes in the assay. 
In profile radiography carried out with the same technical characteristics and times 
(before noon) the height of the intervertebral space in millimeters will be measured, this 
being the 
variable that will be compared with the measurements that occurred over time (6 and 
12 months after MSV implantation). An increase in height will be understood as an 
indication of rehydration disc associated with an increase in proteoglycans and 
cellularity of the NP. Descriptive analysis of the observed values will be expressed by 
the mean, standard derivation, interval of 95% confidence of the mean. To find out if 
there are differences between baseline and at 6 and 12 months the Wilcoxon 
nonparametric test for paired data will be used. So Optional, the study will be repeated 
at 12 months evaluating changes in the leading. The analysis descriptive of the 
observed values will be expressed by the mean, standard deviation, 95% confidence 
interval of the mean. 
11.2.1.2 Quantitative MRI criteria 
Quantitative density evaluations will be carried out in the “ROIs” (Regions of interest) of 
the area of the nucleus pulposus of the affected segment and of the 3-5 healthy 
neighboring segments in the T2 images taken before the start of treatment and 6 and 
12 months after inclusion. The quotient of the value obtained in the affected segment 
divided by the mean of the healthy segments will be used as a measure of the relative 
water content, with 1.00 being the normal value. The same ROIs should be used for 
the measurements obtained at 3 times, before treatment and 6 and 12 months after. 
The procedure is illustrated in Figure 4 (taken from (Orozco et al., 2011)). The increase 


                                         Disc_allo_MSV protocol. v.1.6 1                             30 
 
in the quotient approaching the value of 1 is will consider a sign of rehydration. The 
descriptive analysis of the values of this variable It will be expressed by the mean, 
standard deviation, 95% confidence interval of the mean. 
To find out if there are differences between baseline and at 6 and 12 months, the no 
test will be used. parametric for paired Wilcoxon data. 
11.3 POPULATION AND ANALYSIS 
Assessment definitions that are created to define the populations of the analyzes in this 
studio. 
11.3.1 Evaluable patients 
A patient will be considered evaluable provided that he has undergone the specified 
interventions (Control or allogeneic MSV). 
11.3.2 Efficacy population (Per protocol (PP) population): 
Secondary efficacy endpoint analysis will be based on all patients who do not have 
incurred in major protocol violations, and have at least one rating final efficacy of the 
graft. 
11.3.3 Safety population: 
It is the population that includes all evaluable patients who have undergone one of the 
three study treatments. The security population will be the population of analysis of the 
safety variables of the treatment. 
11.3.4 Analysis methods 
Descriptive statistics will be made including summary statistics and lists. For the 
comparisons of means at 0, 6 and 12 months a comparison of means using the t-test 
or Wilcoxon test as appropriate (see 11.2). 
11.3.5 Background and demographic characteristics 
Lists by patient of all demographic measures and baseline data will be presented, 
tabulating the following numerical variables: number of valid cases, number of values 
not available, mean, standard deviation, 95% confidence interval of the mean, median, 
minimum and maximum. For the discrete and categorical variables, will present the 
frequency and percentage of each value. 
11.3.6 Security 
 AA and AAG lists will be made showing relationship, causality and severity. 
 Frequency and percentage of AAG 
 Frequency and percentage of AA 
 Laboratory parameters including hematology and biochemistry: leukocytes, absolute 
neutrophil count, platelet count, creatinine, AST (SGOT) / ALT (SGTP), etc. Laboratory 
parameters will be listed by patient and visit and include the reference range values. 
These parameters are will be summarized by baseline and post-baseline visit analysis. 
The analysis will include "n" valid, mean, standard deviation, median, minimum and 
maximum. In addition, the change from baseline will be evaluated as described in 11.2. 
All the Statistical analyzes will be performed with a bilateral significance level of 0.05. 
11.3.7 Efficacy 
Changes in pain, disability and quality of life indices will be described in the baseline 
situation and at 3, 6 and 12 months of treatment, which will be compared as specified 
in 11.2. 
The frequency and percentage of patients presenting signs of regeneration at 12 
months of the different interventions, comparing the values as specified in 11.2. 
11.4 SOFTWARE 
The statistical analysis will be carried out using the statistical package InStat (v.3.06. 
GraphPad 
Software, Inc). 
11.5. DIFFICULTIES AND LIMITATIONS OF THE STUDY 
As noted above, previous clinical trials show that a considerable improvement (up to 
30%) due to the placebo effect. It will therefore be accurate discount this random effect 
before assessing the effects of MSVs. It is therefore, important evolution in the control 
group. 


                                         Disc_allo_MSV protocol. v.1.6 1                             31 
 
Bone marrow donation could be a problem if not enough were found donors. The 
solution to be used, when possible, by patients undergoing treatment with autologous 
mesenchymals (in the trial we are conducting in collaboration with CM Teknon) also as 
allogeneic donors would be the situation ideal, the most economical in terms of 
required means and the most interesting scientifically. 
We have tried to obtain the maximum masking in the test within a design reasonable 
for this first study. While the “single blind” (patient) design is feasible without serious 
complications, the “double blind” (researcher) or “triple” (analysis) various logistical and 
ethical issues, so they have been left for the future. If there are indications of efficacy 
for allogeneic MSV, it will not be possible to perform direct comparison with autologous 
MSVs, so if these are obtained results, a new trial should be designed to directly 
compare the efficacy of both therapeutic alternatives. 
REFERENCES: 
Adams MA, Dolan P & Hutton WC. (1986). The stages of disc degeneration as 
revealed by discograms. The Journal of bone and joint surgery 68, 36-41. 
Adams MA, Freeman BJ, Morrison HP, Nelson IW & Dolan P. (2000). Mechanical 
initiation of intervertebral disc degeneration. Spine (Phila Pa 1976) 25, 1625-1636. 
Aggarwal S & Pittenger MF. (2005). Human mesenchymal stem cells modulate 
allogeneic immune cell responses. Blood 105, 1815-1822. 
Airaksinen O, Brox JI, Cedraschi C, Hildebrandt J, Klaber-Moffett J, Kovacs F, Mannion 
AF, Reis S, Staal JB, Ursin H & Zanoli G. (2006). Chapter 4. European guidelines for 
the management of chronic nonspecific low back pain. Eur Spine J 15 Suppl 2, S192- 
300. 
Aoki Y, Rydevik B, Kikuchi S & Olmarker K. (2002). Local application of disc-related  
cytokines on spinal nerve roots. Spine (Phila Pa 1976) 27, 1614-1617. 
Balague F, Mannion AF, Pellise F & Cedraschi C. (2007). Clinical update: low back 
pain. Lancet 369, 726-728. 
Bernardo ME, Locatelli F & Fibbe WE. (2009). Mesenchymal stromal cells. Ann N Y 
Acad Sci 1176, 101-117. 
Bernardo ME, Pagliara D & Locatelli F. (2011). Mesenchymal stromal cell therapy: a 
revolution in Regenerative Medicine? Bone Marrow Transplant. 
Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montagna 
D, Maccario R, Villa R, Daidone MG, Zuffardi O & Locatelli F. (2007). Human bone 
marrow derived mesenchymal stem cells do not undergo transformation after longterm 
in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 67, 
9142-9149. 
Bibby SR, Jones DA, Ripley RM & Urban JP. (2005). Metabolism of the intervertebral 
disc:effects of low levels of oxygen, glucose, and pH on rates of energy metabolism of 
bovine nucleus pulposus cells. Spine (Phila Pa 1976) 30, 487-496. 
Blanco JF, Graciani IF, Sanchez-Guijo FM, Muntion S, Hernandez-Campo P, 
Santamaria C, Carrancio S, Barbado MV, Cruz G, Gutierrez-Cosio S, Herrero C, San 
Miguel JF, Brinon JG & Del Canizo MC. (2010). Isolation and Characterization of 
Mesenchymal Stromal Cells From Human Degenerated Nucleus Pulposus: 
Comparison With Bone Marrow Mesenchymal Stromal Cells From the Same Subjects. 
Spine 35, 2259-2265. 
Brox JI, Reikeras O, Nygaard O, Sorensen R, Indahl A, Holm I, Keller A, Ingebrigtsen 
T, Grundnes O, Lange JE & Friis A. (2006). Lumbar instrumented fusion compared 
withcognitive intervention and exercises in patients with chronic back pain after 
previoussurgery for disc herniation: a prospective randomized controlled study. Pain 
122, 145-155. 
Brox JI, Sorensen R, Friis A, Nygaard O, Indahl A, Keller A, Ingebrigtsen T, Eriksen 
HR, Holm I, Koller AK, Riise R & Reikeras O. (2003). Randomized clinical trial of 
lumbar instrumented fusion and cognitive intervention and exercises in patients with 
chronic low back pain and disc degeneration. Spine 28, 1913-1921. 


                                         Disc_allo_MSV protocol. v.1.6 1                             32 
 
Coppes MH, Marani E, Thomeer RT, Oudega M & Groen GJ. (1990). Innervation of 
annulus fibrosis in low back pain. Lancet 336, 189-190. 
Chang CH, Kuo TF, Lin FH, Wang JH, Hsu YM, Huang HT, Loo ST, Fang HW, Liu HC 
& Wang WC. (2011). Tissue engineering-based cartilage repair with mesenchymal 
stem cells in a porcine model. J Orthop Res. 
Dashtdar H, Rothan HA, Tay T, Ahmad RE, Ali R, Tay LX, Chong PP & Kamarul T. 
(2011). A preliminary study comparing the use of allogenic chondrogenic pre-
differentiated and undifferentiated mesenchymal stem cells for the repair of full 
thickness articular cartilage defects in rabbits. J Orthop Res 29, 1336-1342. 
Davidson M & Keating JL. (2002). A comparison of five low back disability 
questionnaires: reliability and responsiveness. PhysTher 82, 8-24. 
De la Fuente R, Bernad A, Garcia-Castro J, Martin MC & Cigudosa JC. (2010). 
Retraction: Spontaneous human adult stem cell transformation. Cancer Res 70, 6682. 
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, 
Keating A, Prockop D & Horwitz E. (2006). Minimal criteria for defining multipotent 
mesenchymal stromal cells. The International Society for Cellular Therapy position 
statement. Cytotherapy 8, 315-317. 
Errico TJ, Gatchel RJ, Schofferman J, Benzel EC, Faciszewski T, Eskay-Auerbach M & 
Wang JC. (2004). A fair and balanced view of spine fusion surgery. Spine J 4, S129-
S138. 
Eyre DR & Muir H. (1976). Types I and II collagens in intervertebral disc. Interchanging 
radial distributions in annulus fibrosus. Biochem J 157, 267-270. 
Fairbank J, Frost H, Wilson-MacDonald J, Yu LM, Barker K & Collins R. (2005). 
Randomised controlled trial to compare surgical stabilisation of the lumbar spine with 
an intensive rehabilitation programme for patients with chronic low back pain: the MRC 
spine stabilisation trial. BMJ 330, 1233. 
Fassett DR, Kurd MF & Vaccaro AR. (2009). Biologic solutions for degenerative disk 
disease. J Spinal DisordTech 22, 297-308. 
Flanagan MN & Chung BU. (1986). Roentgenographic changes in 188 patients 10-20 
years after discography and chemonucleolysis. Spine (Phila Pa 1976) 11, 444-448. 
Fritzell P, Hagg O, Wessberg P & Nordwall A. (2001). 2001 Volvo Award Winner in 
Clinical Studies: Lumbar fusion versus nonsurgical treatment for chronic low back pain: 
a multicenter randomized controlled trial from the Swedish Lumbar Spine Study Group. 
Spine 26, 2521-2532. 
Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, Bullinger M, 
Kaasa S, Leplege A, Prieto L & Sullivan M. (1998). Cross-validation of item selection 
and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA 
Project. International Quality of Life Assessment. J Clin Epidemiol 51, 1171-1178. 
Guyer RD, McAfee PC, Banco RJ, Bitan FD, Cappuccino A, Geisler FH, Hochschuler 
SH, Holt RT, Jenis LG, Majd ME, Regan JJ, Tromanhauser SG, Wong DC & 
Blumenthal SL. (2009). Prospective, randomized, multicenter Food and Drug 
Administration investigational device exemption study of lumbar total disc replacement 
with the CHARITE artificial disc versus lumbar fusion: five-year follow-up. Spine J 9, 
374-386. 
Harrop JS, Youssef JA, Maltenfort M, Vorwald P, Jabbour P, Bono CM, Goldfarb N, 
Vaccaro AR & Hilibrand AS. (2008). Lumbar adjacent segment degeneration and 
disease after arthrodesis and total disc arthroplasty. Spine 33, 1701-1707. 
Henriksson HB, Svanvik T, Jonsson M, Hagman M, Horn M, Lindahl A & Brisby H. 
(2009) Transplantation of human mesenchymal stems cells into intervertebral discs in a 
xenogeneic porcine model. Spine 34, 141-148. 
Hilibrand AS & Robbins M. (2004). Adjacent segment degeneration and adjacent 
segment disease: the consequences of spinal fusion? Spine J 4, 190S-194S. 
Hiyama A, Mochida J, Iwashina T, Omi H, Watanabe T, Serigano K, Tamura F & Sakai 
D. (2008). Transplantation of mesenchymal stem cells in a canine disc degeneration 
model. J OrthopRes 26, 589-600. 


                                         Disc_allo_MSV protocol. v.1.6 1                             33 
 
Hohaus C, Ganey TM, Minkus Y & Meisel HJ. (2008). Cell transplantation in lumbar 
spine disc degeneration disease. EurSpine J 17 Suppl 4, 492-503. 
Horner HA & Urban JP. (2001). 2001 Volvo Award Winner in Basic Science Studies: 
Effect of nutrient supply on the viability of cells from the nucleus pulposus of the 
intervertebral disc. Spine (Phila Pa 1976) 26, 2543-2549. 
Huskisson EC. (1974). Measurement of pain. Lancet 2, 1127-1131. 
Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD & Mao N. (2005). Human 
mesenchymal stem cells inhibit differentiation and function of monocyte-derived 
dendritic cells. Blood 105, 4120-4126. 
Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, 
Deans RJ & McIntosh KR. (2005). T cell responses to allogeneic human mesenchymal 
stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 12, 47-57. 
Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI & Lazarus 
HM. (2000). Rapid hematopoietic recovery after coinfusion of autologous-blood stem 
cells and culture-expanded marrow mesenchymal stem cells in advanced breast 
cancer patients receiving high-dose chemotherapy. J Clin Oncol 18, 307-316. 
Konings JG & Veldhuizen AG. (1988). Topographic anatomical aspects of lumbar disc 
puncture. Spine (Phila Pa 1976) 13, 958-961. 
Kwon B, Katz JN, Kim DH & Jenis LG. (2006). A review of the 2001 Volvo Award 
winner in clinical studies: lumbar fusion versus nonsurgical treatment for chronic low 
back pain: a multicenter randomized controlled trial from the Swedish lumbar spine 
study group. Spine 31, 245-249. 
Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, 
McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR, Jr., 
Moseley AB & Bacigalupo A. (2005). Cotransplantation of HLA-identical sibling culture-
expanded mesenchymal stem cells and hematopoietic stem cells in hematologic 
malignancy patients. Biol Blood Marrow Transplant 11, 389-398. 
Le Blanc K & Ringden O. (2007). Immunomodulation by mesenchymal stem cells and 
clinical experience. J Intern Med 262, 509-525. 
Le Blanc K, Tammik L, Sundberg B, Haynesworth SE & Ringden O. (2003). 
Mesenchymal  stem cells inhibit and stimulate mixed lymphocyte cultures and 
mitogenic responses independently of the major histocompatibility complex. Scand J 
Immunol 57, 11-20. 
Le Maitre CL, Baird P, Freemont AJ & Hoyland JA. (2009). An in vitro study 
investigating the survival and phenotype of mesenchymal stem cells following injection 
into nucleus pulposus tissue. Arthritis Res Ther 11, R20. 
Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, Hou Y, Zeng X, Gilkeson GS & Sun L. 
(2010). Allogenic mesenchymal stem cells transplantation in refractory systemic lupus 
erythematosus: a pilot clinical study. Ann Rheum Dis 69, 1423-1429. 
Miyamoto T, Muneta T, Tabuchi T, Matsumoto K, Saito H, Tsuji K & Sekiya I. (2010). 
Intradiscal transplantation of synovial mesenchymal stem cells prevents intervertebral 
disc degeneration through suppression of matrix metalloproteinase-related genes in 
nucleus pulposus cells in rabbits. Arthritis Res Ther 12, R206. 
Modic MT & Ross JS. (2007). Lumbar degenerative disk disease. Radiology 245, 43-
61. Nerlich AG, Boos N, Wiest I & Aebi M. (1998). Immunolocalization of major 
interstitial collagen types in human lumbar intervertebral discs of various ages. 
Virchows Arch 432, 67-76. 
Orozco L, Soler R, Morera C, Alberca M, Sanchez A & Garcia-Sancho J. 
(2011).Intervertebral Disc Repair by Autologous Mesenchymal Bone Marrow Cells: A 
PilotStudy. Transplantation 92, 822-828. 
Osti OL, Fraser RD & Vernon-Roberts B. (1990). Discitis after discography. The role of 
prophylactic antibiotics. The Journal of bone and joint surgery 72, 271-274. 
Rihn JA, Lawrence J, Gates C, Harris E & Hilibrand AS. (2009). Adjacent segment 
disease after cervical spine fusion. InstrCourse Lect 58, 747-756. 


                                         Disc_allo_MSV protocol. v.1.6 1                             34 
 
Risbud MV, Albert TJ, Guttapalli A, Vresilovic EJ, Hillibrand AS, Vaccaro AR & Shapiro 
IM.(2004). Differentiation of mesenchymal stem cells towards a nucleus pulposus-like 
phenotype in vitro: implications for cell-based transplantation therapy. Spine 29, 2627-
2632. 
Robaina FJ. (2006). Situación actual de la cirugía de la columna vertebral degenerativa 
aplicada al manejo del dolor lumbar crónico: Estenosis de canal. Discopatía 
degenerativa, resultados basados en la evidencia científica. Rev Soc Esp Dolor 13, 
167-172. 
Roth WK. (2010). Quarantine Plasma: Quo vadis? Transfus Med Hemother 37, 118-
122. 
Roughley PJ. (2004). Biology of intervertebral disc aging and degeneration: 
involvement of the extracellular matrix. Spine (Phila Pa 1976) 29, 2691-2699. 
Sakai D, Mochida J, Iwashina T, Hiyama A, Omi H, Imai M, Nakai T, Ando K & Hotta T. 
(2006). Regenerative effects of transplanting mesenchymal stem cells embedded  in 
atelocollagen to the degenerated intervertebral disc. Biomaterials 27, 335-345.  
Sakai D, Mochida J, Iwashina T, Watanabe T, Nakai T, Ando K & Hotta T. (2005). 
Differentiation of mesenchymal stem cells transplanted to a rabbit degenerative disc 
model: potential and limitations for stem cell therapy in disc regeneration. Spine 30, 
2379-2387. 
Shimomura K, Ando W, Tateishi K, Nansai R, Fujie H, Hart DA, Kohda H, Kita K, 
Kanamoto T, Mae T, Nakata K, Shino K, Yoshikawa H & Nakamura N. (2010). The 
influence of skeletal maturity on allogenic synovial mesenchymal stem cell-based 
repair of cartilage in a large animal model. Biomaterials 31, 8004-8011. 
Siepe CJ, Tepass A, Hitzl W, Meschede P, Beisse R, Korge A & Mayer HM. (2009). 
Dynamics of improvement following total lumbar disc replacement: is the outcome 
predictable? Spine 34, 2579-2586. 
Sotiropoulou PA & Papamichail M. (2007). Immune properties of mesenchymal stem 
cells. Methods Mol Biol 407, 225-243. 
Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN & Papamichail M. (2006). 
Interactions between human mesenchymal stem cells and natural killer cells. Stem 
Cells 24, 74-85. 
Strange DG & Oyen ML. (2012). Composite hydrogels for nucleus pulposus tissue 
engineering. J Mech Behav Biomed Mater 11, 16-26. 
Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A & Shi S. (2009). 
Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic 
lupus erythematosus mice and humans. Stem Cells 27, 1421-1432. 
Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, Hua B, Liu B, Ye S, Hu X, Xu W, 
Zeng X, Hou Y, Gilkeson GS, Silver RM, Lu L & Shi S. (2010). Umbilical cord 
mesenchymal stem cell transplantation in severe and refractory systemic lupus 
erythematosus. Arthritis Rheum 62, 2467-2475. 
Sztrolovics R, Grover J, Cs-Szabo G, Shi SL, Zhang Y, Mort JS & Roughley PJ. 
(2002). Characterization of versican and its message in human articular cartilage and 
intervertebral disc. J Orthop Res 20, 257-266. 
Torsvik A, Rosland GV, Svendsen A, Molven A, Immervoll H, McCormack E, Lonning 
PE, Primon M, Sobala E, Tonn JC, Goldbrunner R, Schichor C, Mysliwietz J, Lah TT, 
Motaln H, Knappskog S & Bjerkvig R. (2010). Spontaneous malignant transformation of 
human mesenchymal stem cells reflects cross-contamination: putting the research field 
on track - letter. Cancer Res 70, 6393-6396. 
Urban JP, Smith S & Fairbank JC. (2004). Nutrition of the intervertebral disc. Spine 
(Phila Pa 1976) 29, 2700-2709. 
Vadala G, Studer RK, Sowa G, Spiezia F, Iucu C, Denaro V, Gilbertson LG & Kang JD. 
(2008). Coculture of bone marrow mesenchymal stem cells and nucleus pulposus cells 
modulate gene expression profile without cell fusion. Spine 33, 870-876. 
Vogel G. (2010). Cell biology. To scientists' dismay, mixed-up cell lines strike again. 
Science 329, 1004. 


                                         Disc_allo_MSV protocol. v.1.6 1                             35 
 
Watanabe T, Sakai D, Yamamoto Y, Iwashina T, Serigano K, Tamura F & Mochida J. 
(2009). Human nucleus pulposus cells significantly enhanced biological properties in a 
coculture system with direct cell-to-cell contact with autologous mesenchymal stem 
cells. J OrthopRes 28, 623-630.  
Yan H & Yu C. (2007). Repair of full-thickness cartilage defects with cells of different 
origin in a rabbit model. Arthroscopy 23, 178-187. 
Yang H, Wu J, Liu J, Ebraheim M, Castillo S, Liu X, Tang T & Ebraheim NA. (2010). 
Transplanted mesenchymal stem cells with pure fibrinous gelatin-transforming growth 
factor-beta1 decrease rabbit intervertebral disc degeneration. Spine J 10, 802-810.  
Yang SH, Wu CC, Shih TT, Sun YH & Lin FH. (2008). In vitro study on interaction 
between human nucleus pulposus cells and mesenchymal stem cells through paracrine 
stimulation. Spine 33, 1951-1957. 
Zhao CQ, Wang LM, Jiang LS & Dai LY. (2007). The cell biology of intervertebral disc 
aging and degeneration. Ageing Res Rev 6, 247-261 
 
 
 


                                         Disc_allo_MSV protocol. v.1.6 1                             36 
 
ANNEX I: PRODUCT DOSSIER / INVESTIGATOR'S MANUAL 
The product under study is made up of allogeneic mesenchymal cells (MSV) isolated 
and expanded under GMP conditions following our protocol authorized by the AEMPS 
(PEI Num. 10-134; a copy of the notification is added at the end of this document). The 
details of this product are briefly described below and with more detail in section 6.1 of 
the Protocol report. 
General characteristics of the product under study. 
The investigational drug or product is allogeneic mesenchymal cells from bone marrow, 
and processed according to the Standard Work Procedure of the IBGM of Valladolid 
(MSV), suspended in isotonic Ringer-lactate medium with albumin 0.5% human and 5 
mM glucose. Cell dose: 25x106 ± 5x106 MSV, packed in 5 ml syringe containing 2 ml 
of cell suspension and labeled with the name "Disc_MSV_allo" and the reference numb                             
er. Demonstrated stability is> 12 hours at 4-20 ºC (Orozco et al., 2011). The entire 
process of obtaining the MSV is carried out by qualified specialists in cell cultures and 
NCF, and is developed in the Unit of Cell Production of the IBGM (UVa Scientific Park), 
meeting GMP criteria and following protocols approved by the AEMPS (PEI No. 10-
134). The procedure of collection, cultivation and expansion is detailed in section 6.1.1 
of the protocol. In the validations carried out, it has been shown that the MSV have the 
typical characteristics MSC defined by the Society for Cellular Therapy (Dominici et al., 
2006):  
1) Adherence to plastic in cultivation;  
2) Expression of CD73, CD90 and CD105 antigens.  
3) Absence of hematopoietic antigens, markers of monocytes, macrophages and B 
lymphocytes. 
4) In vitro differentiation capacity in osteoblasts, adipocytes and chondrocytes. The cell 
product, MSV, is the same that we used in the EudraCT 2008-001191- assay. 68; 
intervertebral disc) whose results demonstrate feasibility and safety and have been 
recently published (Orozco et al., 2011). We are using the same product in the Eudra-
CT 2009-017405-11 (NCT01183728, autologous MSVs in knee osteoarthritis) and 
Eudra-CT 2011-005321-51 (NCT01586312; allogeneic MSV in gonarthrosis) with 
hopeful indications of efficacy and without there having been, for the time being, 
adverse effects. 
Our Cell Production Unit of the IBGM, according to GMPs, directed by Dr. Ana 
Sánchez, was the first Clean Room authorized by the AEMPS in the Public System and 
currently participates in eight clinical trials, several of them with mesenchymal cells of 
the bone marrow. It has an MSC preparation protocol authorized by the AEMPS (PEI 
No. 10-134, Valladolid mesenchymal cells or MSV). It has a stable staff with training in 
quality control, which includes 12 people. Had given recently originated a Technology-
Based Company owned by the University, Citospin S.L. that adds additional nuances to 
cell production and features new and modern facilities in the Science Park of the 
University of Valladolid. 
 
INVESTIGATOR'S MANUAL. 
General protocol: 
1. Culture of MSV cells with GMP methodology of the Cell Therapy Unit of the IBGM to 
manufacture the mesenchymal cell product (for administrative purposes drug) released 
at 3-4 weeks in a suspension with 25106 ± 5x106 in 2 mL of Ringer-lactate isotonic 
medium with 0.5% human albumin and glucose 5mM and a cell viability ≥ 80%, loaded 
into a syringe and labeled, having proven negative microbiological results for 
microorganisms (Gram-) and mycoplasma and endotoxin level less than 0.5 EU / mL. 
Details about the obtaining donor bone marrow by puncture-aspiration and cell 
processing 
They are described in detail in sections 5.3 and 6.1.6 of the protocol. 
2. Injection of 2 mL of the MSV suspension into the nucleus pulposus area of the disc 
degenerated under radiological control to ensure administration in the correct location. 


                                         Disc_allo_MSV protocol. v.1.6 1                             37 
 
In the control arm of the test, 2 mL of the 1% mepivacaine in saline solution in 
paravertebral muscles close to the injury. 
3. Evaluate the feasibility, safety and evidence of efficacy of the treatment under 
subjective, objective and imaging clinical criteria that confirm or deny the improvement 
of symptoms and improvement of dehydration, as well as its maintenance in the time. 
Procedure for intradiscal application of MSV: 
The collection, preparation and transport of the MSV will take place in the morning and 
the cells will be applied within 12 hours of packaging. The patient will complete the 
procedures administrative procedures corresponding to outpatient admission and 
treatment, following the following procedure: Antibiotic prophylaxis will be performed 
with 2 gr of IV cefazolin or 1 gr of IV vancomycin in case of allergy. Cell implantation is 
carried out under mild sedation and radiological control. The cells are injected by 
puncturing the disc avoiding neurovascular elements (Konings & Veldhuizen, 1988). 
After double  brushing the region with an aqueous solution of povidone-iodine (or 
chlorhexidine in patients allergic to iodine), the field is delimited with sterile sheets and 
local anesthesia (Scandicain 1%) to the skin, subcutaneous tissue and muscle near the 
puncture. 
With anteroposterior fluoroscopy, a line is marked on the skin vertical corresponding to 
the projection of the spinous process with a dermographic pencil sterile. Then a 
perpendicular line is drawn corresponding to the projected image of a Kirschner wire 
aligned with the intervertebral space to be treated and a 20G spinal needle tilted 25 to 
35 degrees toward the midline at one point located 8 to 9 cm (depending on the patient 
morphotype) from the midline. In this moment, fluoroscopy is switched to the lateral 
position to ensure that penetration of the needle follows the correct direction until the 
nucleus pulposus is reached. After verify the correct position of the needle in the 
nucleus pulposus both in the fluoroscopic view antero-posterior and lateral, the 
suspension of cells is injected slowly inject slowly. Using this procedure, we had no 
incidents in any of the 10 patients from our previous study (Orozco et al., 2011). 
 
Post-treatment guidelines 
The patient is discharged after a 2-hour observation period. Not prescribed Lumbostat 
corset and walking is allowed for moderate periods. The work activity for a week. 
Exercises are prescribed to tone the paravertebral muscles and abdominals, which 
begin one month after the intervention. Medication analgesic is adapted to the needs of 
each patient and use should be avoided as far as possible of anti-inflammatories. 
Long-term follow-up will consist of clinic visits and radiographic and MR monitoring as 
specified in section 7.2 of the protocol ("Trial Schedule"). 
 
Concomitant treatments  
Relevant concomitant medications taken by the patient will be recorded in the CRD 
regularly due to other parallel treatments allowed during the study. During treatment 
and subsequent follow-up, corticosteroids should be avoided as much as possibleas 
well as anti-inflammatory therapy. If it is considered necessary to administer them, you 
should be noted in the clinical history and CRD. 
Drug accounting 
The product under study or medicine is produced individually by starting from the bone 
marrow from each donor. In all cases, the MSV will be registered and identified 
produced for each patient at the IBGM. 
Management of study medication 
The study medication, properly packaged MSV in a thermostatic container, was 
transported immediately after production to the application center. You have 12 hours 
of stability at room temperature and is applied in the operating room as an injection into 
the knee joint. 
 
 


                                         Disc_allo_MSV protocol. v.1.6 1                             38 
 
ANNEX II: PATIENT INFORMATION SHEET 
Study Title: Treatment of Lumbar Degenerative Disc Disease with Cells 
allogeneic mesenchymals (MSV *). * "Ex Vivo" expanded bone marrow 
progenitor cells with GMP procedure of the IBGM of Valladolid. 
EudraCT: 2012-004444-30 
 
Dear Patient: 
This fact sheet may contain words that you do not understand. In such case, for Please 
ask the doctor responsible for the study or the personnel participating in the study to 
Explain any words or information that you do not clearly understand. When there is 
understood all the information you will be asked to sign a consent form informed to 
participate in the study. 
As a patient diagnosed with Degenerative Disc Disease (DDL), which is a degeneration 
or "wear" of the spinal disc, suffer from back pain and other discomfort rebellious to the 
usual treatments and whose evolution is presumably towards a greater deterioration, 
without meaning that this is necessarily linked to persistence or increased symptoms. 
In addition to the usual treatment methods, which you may already have received, 
there is a new treatment option that may perhaps achieve restoration, by less partial, 
the intervertebral disc to a state close to normal with relief of the symptom. This new 
treatment consists of the injection into the intervertebral disc of mesenchymal stem 
cells obtained from a healthy donor (allogeneic MSV) and expanded "Ex vivo" in the 
laboratory. MSV treatment will be applied to half of the patients participating in this trial. 
The other half (control group) will receive a similar injection, but without cells. Whether 
a specific patient is included in one or the other The group will be determined randomly 
and will not be made public until the end of the clinical trial. One time after the clinical 
trial, patients in the control group will be offered the possibility of receive mesenchymal 
cell treatment if it proves to be more effective than control. 
The goal of this study, authorized by the Clinical Research Ethics Committee of the 
Hospital Clínico Universitario de Valladolid and controlled by the Spanish Agency for 
Medicines and Health Products, is to determine the viability, safety, and indications 
efficacy of the new therapeutic proposal. 
A total of 24 patients will participate in this study. If you decide to participate, it will be 
required carry out the stipulated tests and procedures that are necessary for the 
treatment in the assigned group, as well as clinical and radiological follow-up visits that 
have been scheduled on specific dates and that, in the interests of the reliability of the 
investigation, must be respected. 
 
Visiting program 
The patient visit program will be as follows: 
Pre-Inclusion: Patients who come to the consultation and whose diagnostic orientation 
is based on in the medical history and complementary examinations suggest that it 
would be beneficial their inclusion in the clinical trial (CT), presenting all the inclusion 
criteria and none exclusion, they will be prescribed the treatment schedule according to 
the norm and then They will be informed of the possibility of inclusion in the EC. They 
will be given the “Sheet of Information to the Patient” and, if their decision is affirmative, 
the procedures for inclusion in a next visit. 
Inclusion (Visit 0): May require more than one visit. If the patient decides to join the 
trial you will be asked to sign the “Informed Consent Document”. Will be requested then 
new radiographic and Magnetic Resonance Imaging (MRI) scans with the mandatory 
characteristics of the study, except if these examinations had already been carried out 
within a period of no more than 6 months. The analysis and determinations in sera  will 
be carried out regulations that include determination of HIV, Hepatitis and Lúes. In the 
case of women at childbearing age, a urine sample will also be requested to perform a 
test of pregnancy. The low back pain evaluation questionnaires (VAS), disability will be 
passed (Oswestry) and quality of life (SF-12). The MRI will be performed and 


                                         Disc_allo_MSV protocol. v.1.6 1                             39 
 
scheduled on the day of the intervention (V1). It will be verified that all the inclusion 
criteria are met for participate in the study, in which case the visit for the intervention 
will be scheduled. The observer agency (CRO) will determine by a random procedure if 
you will enter the control or experimental group, and this allocation will remain secret 
from the patients until the end of the clinical trial. 
Visit 1 (day 1): In it, the cultured cells will be implanted (or the hydrogel) in the 
diseased intervertebral disc, following the procedure similar to an injection. 
Follow-up visits (2 to 5): Must be presented for controls at 8 days and at 3, 6 and 12 
months after the intervention, in which the clinical, analytical and medical controls will 
be carried out. image agreed in the protocol. At the end of this period, the analysis of 
the data and obtaining conclusions from the study, but the medical team that has 
treated you will remain at your disposal for long-term follow-up and follow-up with other 
treatments if necessary. The patient is expected to undergo the program of follow-up 
specified in the preceding paragraphs for a period that will last approximately one year 
after trial treatment. Subsequently, the patient You must report any incident that could 
be related to the clinical trial. 
Withdrawal from the study 
Your participation in this study is completely voluntary, and you may withdraw from it at 
any time moment, without having to give explanations and without compromising in any 
way the treatment that you have to receive. The study doctor may also withdraw you 
from it at any time if you consider it is in your best interest or that it does not meet the 
necessary requirements to participate because it requires some treatment not allowed 
in the study, if you do not follow the instructions, if you are a woman and stay pregnant 
or if the study is canceled. The Essay Promoter may also interrupt it ahead of schedule 
if they deem it necessary. 
Possible risks and drawbacks 
As with all effective medications or treatments, some unwanted effect, which we 
consider to have a very low probability of Present. We consider that the risks of your 
treatment are no greater than those that involves the usual discography technique, 
which involves percutaneous puncture of the disc spinal cord under radiographic 
control and that includes the risk associated with sedation or anesthesia, infections, 
bleeding, etc. 
The proposed treatment is novel, since no treatment has been carried out to date with 
Allogeneic mesenchymal cells for lumbar degenerative disc disease. As in all research 
studies, there may be short-term and long-term risks, some known and others that are 
still unknown, but we do not expect any problem from new health for participating in 
this study. The main risks that we can imagine are: 
At the local level, the disc injection has a small risk of causing bleeding, inflammation 
or even infection, which should be controllable by procedures usual. 
The most serious risks could arise from immune reactions caused by the allogenicity of 
MSV, causing either rejection of the implanted cells or aggression phenomena against 
host cells. It is known, however, that mesenchymal cells are highly immune tolerant 
and unlikely that give rise to these phenomena. On the other hand, mesenchymal cells 
have been used in several previous clinical trials, usually to treat autoimmune 
diseases. 
In the previous experiences published so far, no Noteworthy Adverse Events 
Associated with Treatment. I actually know has reported the opposite therapeutic 
effect, inducing immune tolerance, even in these autoimmune disease patients, in 
which the balance of the immune system can easily fall apart. For these reasons we 
think that the problems derived from Immune reactions are very unlikely. It should be 
emphasized, however, that, as the mesenchymal cells have so far been applied in a 
limited number of cases, Rare effects may appear that are unknown to us at this time. 
On In any case, if you experience any problem during the study, you must 
communicate it immediately to the responsible doctor. 


                                         Disc_allo_MSV protocol. v.1.6 1                             40 
 
In rare cases when a nurse, doctor, or lab technician is exposed to a patient's blood, 
tissue, or body fluid due to a needle stick needle, cut, or splash, such blood, tissue, or 
body fluid may need to be tested to determine the possible existence of certain viral 
infections, such as hepatitis B and C and HIV This test would allow that person to 
receive appropriate counseling, and the treatment if necessary. In these cases, the 
study doctor will ask you to undergo any necessary diagnostic test (usually a blood 
test), provide information relevant to your health and advise you on next steps. The 
confidentiality of your data will be respected at all times. 
During the development of this clinical trial, medication with corticosteroids and anti-
inflammatories, as these treatments can interfere with therapy cellular or complicate 
the interpretation of your results. If it is necessary to implement these treatments, will 
be done in the shortest possible way. 
It must also be accepted that there may be drawbacks that make it impossible to cell 
transplantation such as fortuitous failures in the laboratory, growth of pathogenic germs 
on the cell product, accidents during transportation or situations Similar. If this 
undesirable and unlikely situation happened, you would be offered to repeat the 
process. 
New information 
In the event that important new information appears during the course of the trial about 
the study treatment you have received, your doctor will inform you adequately about 
the implications it may have on your participation in the same. 
Study review and approval 
The performance of this study and all its details has been reviewed and approved by 
the Ethical Committee for Clinical Research of the Hospital Clínico Universitario de 
Valladolid and by the pertinent Health Regulatory Authorities. 
Confidentiality 
Access to your clinical-care data will be done keeping the strictest confidentiality so 
that personal privacy is not violated. Your data will be treated as so that the information 
obtained cannot identify you or be associated with you. 
In this way you will not be able to be identified during the analysis, in the presentation 
of the results of the study or in publications related to the study. 
If you agree to participate in the study, you authorize that in addition to the doctor and 
his team, your medical records are reviewed by authorized staff of the Study Sponsor, 
by the organization designated by the Sponsor to coordinate the study (CRO), by the 
Regulatory Health Authorities and representatives of the Research Ethics Committee 
Clinic that has approved the study. During the study, you are guaranteed strict 
compliance with the Law of protection of personal data (in Spain, Law 15/1999 of 
December 13, Personal data protection). In any case, you can withdraw consent 
informed for the processing of your personal data by contacting the researcher.  
Gratuitous character  
All trial-related procedures, tests, and visits that are carried out will not entail any cost 
since it is covered by funds for aid to the investigation. 
Compensation 
If, as a result of your participation in the trial, you present some type of adverse 
reaction to the medication or if the study has effects on your health, the research team 
study doctors will provide the necessary medical care and notify the Promoter. All 
patients participating in the study will be insured according to the applicable and 
current national and international legal requirements. The Promoter of the study, claims 
to have subscribed an insurance policy with the company HDI HANNOVER 
INTERNACIONAL with the number 1301001/008413, for civil liability, which covers the 
damages that could result as a consequence of the clinical trial in the person or 
persons to be carried out, in accordance with the provisions of the current legislation. 
In no way, the fact of signing the informed consent means that you lose or waives the 
legal rights that may correspond or exempts the researchers, the promoter of the study 


                                         Disc_allo_MSV protocol. v.1.6 1                             41 
 
and the institutions involved in it of the obligations and corresponding professional 
responsibilities. 
Acknowledgwments 
Thank you very much for reading this clinical trial information document. Please take 
enough time before deciding if you want to participate. If you decide to take part in the 
study, please sign the informed consent form. You will be given a copy of this 
informative document and the consent document for you to save. 
If at any time during the study you would like to ask a question regarding the treatment 
or your condition, or in case of any emergency, do not hesitate to contact contact with: 
 
Dr ………………………………... …………………………… Telephone ……………… 
 
Dr ………………………………... …………………………… Telephone ……………. 
 
INFORMED CONSENT DOCUMENT 
Study Title: Treatment of lumbar degenerative disc disease with mesenchymal cells 
allogeneic (MSV *).* "Ex Vivo" expanded bone marrow progenitor cells with the GMP 
procedure of the IBGM of Valladolid 
EudraCT: 2012-004444-30. Code: Disc_allo_MSV 
I ………………………………………………………………………. (Name and surname). 
I declare that: 
I have read the information sheet that has been given to me. 
I have been able to ask questions about the study. 
I have received enough information about the study. 
I have spoken to............................................. ......................... (Investigator's name) 
I understand that my participation is voluntary and that I can withdraw from the study 
when want, without having to give explanations and without this having an impact on 
my medical care. 
Having carefully examined all the circumstances, I freely lend my compliance to 
participate in the study. 
.................................. ................ ............................................... 
(date) (participant's signature) 
................................. ................. .............................................. 
(date) (researcher's signature) 
 
 
 
ALTERNATIVE CONSENTS 
 
ORAL CONSENT DOCUMENT BEFORE WITNESSES 
Study Title: Treatment of lumbar degenerative disc disease with mesenchymal cells 
allogeneic (MSV *). * "Ex Vivo" expanded bone marrow progenitor cells with the GMP 
procedure of the IBGM of Valladolid  EudraCT: 2012-004444-30. Code: Disc_allo_MSV 
Me,................................................ ................................, (name and surname) I declare 
under my responsibility that ................................................ .. (Name of trial participant): 
You have received the information sheet about the study. 
You have been able to ask questions about the study. 
You have received enough information about the study. 
Has been informed by .............................................. ............. (name of the researcher). 
You understand that your participation is voluntary and that I may withdraw from the 
study when you want, without having to explain and without having an impact on your 
medical care. 
Once all the circumstances have been carefully examined, he freely lends his 
compliance to participate in the study. 
.................................. ................ ............................................... 


                                         Disc_allo_MSV protocol. v.1.6 1                             42 
 
(date) (witness signature) 
.................................. ................ ............................................... 
(date) (researcher's signature) 
 
 
 
 
 
 
REPRESENTATIVE’s CONSENT DOCUMENT 
Study Title: Treatment of lumbar degenerative disc disease with mesenchymal 
cells allogeneic (MSV *). 
* "Ex Vivo" expanded bone marrow progenitor cells with the GMP procedure of 
the IBGM of Valladolid 
EudraCT: 2012-004444-30. Code: Disc_allo_MSV 
Me,................................................ ............................ ...................... . (Name and 
surname) 
acting as ............................................... ................. (relationship with the participant) 
from ................................................. ...................... (name of trial participant) 
I declare that: 
I have received the information sheet on the study. 
I have been able to ask questions about the study. 
I have received enough information about the study. 
I have been informed by .............................................. .......... (name of the researcher). 
In my presence it has been given to ..................................... ........ (name of participant) 
all the information pertinently adapted to your level of understanding and he agrees to 
participate. 
And I agree that ............................................ .... (participant's name) 
Will participate in this study. 
.................................. ................ ............................................... 
(date) (representative's signature) 
.................................. ................ ............................................... 
(date) (researcher's signature) 
 
 
 
DOCUMENT OF CONSENT OF DONATION OF CELLS FOR REEXPANSION, 
REIMPLANTATION OR INVESTIGATION 
PLEASE NOTE THAT THIS IS THE INFORMED CONSENT FOR THE DONOR of the 
Disc_allo_MSV trial 
(Checkmark as appropriate) 
-As a patient included in the clinical trial: “…………… ..  EudraCT ……… ..., Code…. 
-As a patient included in the Study “……… .................... EudraCT: ………… Code…. 
In the event that after the cultivation process a greater number of cells is obtained than 
the established to be implanted, I accept that: 
Leftover cells can be preserved and manipulated as convenient to carry out, indistinctly 
and in this order, 1) reapplication of cells for myself if necessary and convenient, 2) 
allogeneic application in another patient who could benefit from them or 3) use in the 
projects of research carried out by the Cell Production Unit at the facilities of the 
Institute of Molecular Biology and Genetics or the Science Park of the University of 
Valladolid. Once these uses have been carried out or when the cells are not useful will 
be destroyed following the standard procedures in this Unit of Production. 
I declare that I have understood the information given to me in this regard and that I 
have been had clarified all the questions or doubts that I have wanted to raise, so I 
freely take the decision to authorize the use of surplus cells, understanding that: 


                                         Disc_allo_MSV protocol. v.1.6 1                             43 
 
 All personal information will be treated confidentially and encrypted for the protection 
of my identity 
 This donation is altruistic and I will not receive any compensation for it 
 I am exempt from any liability that may arise from the use of these cells 
 
Place and Date: …………………………… ..to …… ..of… ..… ..… ..… ..… ..of 201… 
 
NAME AND SURNAME OF PATIENT: …………………………………. 
…………………………………………………………………………………… 
ID Number (Passport): ……………………………. SIGNATURE: 
 
 
 
 
 
RESPONSIBLE PERSON THAT PROVIDES THE INFORMATION: 
NAME AND SURNAME: 
DNI: SIGNATURE 
 
 
 
CELL DONATION CONSENT DOCUMENT FOR ALLOGENIC IMPLANTATION. 
PLEASE NOTE THAT THIS IS INFORMED CONSENT FOR DONORS 
ALTERNATIVES, NOT Included in the MSV_artro trial 
Me,................................................ .................................................. .. (Name and 
surname), with DNI Num ……………………… ..that I will be subjected to an 
intervention of ………………………. at the Hospital Cínico Universitario de Valladolid 
scheduled for the day …………………… I have been informed by 
.............................................. .............. …… .. (Name of researcher) the possibility of 
donating a bone marrow sample, which would be obtained during the surgical 
intervention to which I will be subjected. This sample will be used to obtain 
Mesenchymal stem cells for allogeneic transplantation in the clinical trial entitled 
"Treatment of lumbar degenerative disc disease with allogeneic mesenchymal cells 
(MSV) ". The cells will be handled in the existing White Room at the facilities of the 
Institute of Molecular Biology and Genetics and the Science Park of the University of 
Valladolid. If there is a surplus, I authorize its use for the projects of research carried 
out at these facilities. Once these uses or when the cells are not useful they will be 
destroyed following the procedures standardized in this White Room. 
I declare that I have understood the information that has been provided to me in this 
regard and that it have clarified all the questions or doubts that I wanted to raise, so I 
take freely decide to authorize the use of my bone marrow cells for purposes 
mentioned above, understanding that: 
 All personal information will be treated confidentially and encrypted for the protection 
of my identity 
 This donation is altruistic and I will not receive any compensation for it 
 I am exempt from any liability that may arise from the use of these cells 
Place and Date: …………………………… ..to …… ..of… ..… ..… ..… ..… ..of 201… 
Patient Signature: Investigator Signature 
DNI: ………………… .. DNI: ……………………. 
 
 
 
 
 
 
 


                                         Disc_allo_MSV protocol. v.1.6 1                             44 
 
ANNEX III: HELSINKI STATEMENT 
HELSINKI STATEMENT OF THE WORLD MEDICAL ASSOCIATION 
Ethical Principles for Human Medical Research 
Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964 and 
amended by 29th World Medical Assembly, Tokyo, Japan, October 1975  
35th World Medical Assembly, Venice, Italy, October 1983  
41st World Medical Assembly, Hong Kong, September 1989  
48th General Assembly Somerset West, South Africa, October 1996  
52nd General Assembly, Edinburgh, Scotland, October 2000  
Clarification Note on Paragraph 29, WMA General Assembly, Washington 2002 
Clarification Note on Paragraph 30, WMA General Assembly, Tokyo 2004 
59th General Assembly, Seoul, Korea, October 2008 
 
 
 


                                         Disc_allo_MSV protocol. v.1.6 1                             45 
 
ANNEX IV. NOTIFICATION OF SEVERE ADVERSE EFFECTS 
 
NOTIFICACION DEOF 
SUSPICION OF 
ADVERSE REACTION 
FOR IMP  
 
 
I. 
INFORMACION SOBRE LA REACCIÓN ADVERSA 
II. 
 
<   LA VIDA DEL PACIENTE HA 
ESTADO EN PELIGRO 
<   HOSPITALIZACIÓN 
 
<   PROLONGACIÓN HOSPITALIZACIÓN 
 
<   INCAPACIDAD PERMANENTE O SIGNIFICATIVA 
 
<   RA CLINICAMENTE RELEVANTE 
 
<   PERSISTENCIA DE LA REACCIÓN ADVERSA 
 
<   RECUPERACIÓN 
 
II. INFORMACION DEL MEDICAMENTO EN INVESTIGACIÓN 
 
III. MEDICAMENTOS CONCOMITANTES E HISTORIA CLÍNICA 
23. DATOS IMPORTANTES DE LA HISTORIA CLÍNICA (ej. diagnósticos, alergias, 
embarazos, etc.) 
IV. INFORMATION ON THE SPONSOR 
24a. NOMBRE Y DIRECCION DEL PROMOTOR 
24b. NOMBRE Y DIRECCION DEL INVESTIGADOR 
24c. CODIGO DE LABORATORIO 
(Nº AEM) 
25a. TIPO DE INFORME 
< INICIAL 
< SEGUIMIENTO 
24c. TECNICO DEL PROMOTOR QUE INFORMA 
NOMBRE: 
TELEFONO: 
FIRMA: 
24e. FECHA DEL INFORME 
24f. FECHA DE ENTRADA AEM 
25b. SE ADJUNTA INFORME COMPLEMENTARIO 
 
 
GENERAL INSTRUCTIONS 
1. This form will only be used to report suspected adverse reactions (AR) serious and 
unexpected occurrences with investigational drugs. It is considered medicine under 
investigation, both the specifically investigated product and the control. 
2. Suspected fatal or life-threatening adverse reactions (those that are not having 
mediated an immediate therapeutic intervention would have meant the death of the 
patient) 
2. FECHA DE 
NACIMIENTO 
2a. EDAD 3. SEXO 
3a. 
PE
3b. 
TA
4-6. FECHA 
DE INICIO DE
DÍA MES 
AÑO 
<  
HOMBR
DÍA 
ME
S 
AÑO 
7. DESCRIPCIÓN DE LA REACCIÓN 
ADVERSA (Incluyendo resultados relevantes 
8-13b. CRITERIOS DE GRAVEDAD/ 
DESENLACE 
O 
15. 
SIS 
DIO 
18. FECHAS DE 
INICIO                      
L
19. 
DURACI
Ó
20. ¿REMITIÓ LA 
REACCIÓN AL 
SUSPENDER LA 
MEDICACIÓN?
20a. ¿REMITIÓ LA 
REACCIÓN AL 
REDUCIR LA 
DOSIS?
21. ¿REAPARECIÓ LA 
REACCIÓN AL         
ADMINISTRAR DE NUEVO LA 
MEDICACIÓN?


                                         Disc_allo_MSV protocol. v.1.6 1                             46 
 
They will communicate within a maximum period of 7 calendar days; if not all the 
information is available, this it can be completed within an additional 8 days. Other 
suspected adverse reactions serious and unexpected will be communicated within a 
maximum period of 15 days. 
3. When the available space is insufficient, an additional information sheet will be 
added, correctly identified with the name of the promoter and the number assigned to 
the notification. In this Additional information may include the evaluation of causality 
carried out by the technician that informs. 
 
SPECIFIC INSTRUCTIONS 
1. The protocol code is the one assigned by the promoter to identify the assay. The 
number of the promoter notification is the one that the promoter uses for its file. When it 
comes to information from the tracking number will be used or, if it is modified, the 
number of the initial notification. The "Notification No." space that appears shaded will 
be left unfilled. 
2. The age will be set in years, months, weeks or days as appropriate, but always 
indicating it. the age is not precisely known, it must refer, at least, to the age group to 
which it belongs (p. eg: infant, child, adolescent, adult, elderly). 
3. The adverse reaction will be described in full, indicating the end date of the itself and 
including the results of complementary examinations or laboratory tests that are 
considered of interest. This notification may be accompanied by as many reports as 
deemed convenient for the proper interpretation of the clinical picture suspected of 
being a reaction adverse. 
4. The categories are not mutually exclusive. Assistance in an Emergency Service of a 
Hospital less than 24 hours, hospitalization will not be considered. 
5. Investigational drugs will be identified if possible by their generic name (DOE or 
DCI), indicating when the commercial name is available, or failing that, by the name 
proposed or laboratory code for the product. 
6. In the event that the administration is not daily, an attempt will be made to describe it 
with one of the following possibilities: cyclical, weekly, monthly, yearly or number of 
times it has been used (putting in in this case the dose of each dose, not the total). 
7. The pathological process of the patient to whom the product is intended shall be 
recorded in research, or "healthy volunteer" in case of such. 
8. The duration of treatment until the beginning of the adverse reaction will be stated. 
9. It will be explicitly stated if concomitant drugs have not been taken. In the case of 
considering suspicious one or some of the concomitant drugs will be marked with an 
asterisk (e.g .: * AMOXICILLIN). Medications used to treat the adverse reaction will be 
excluded. 
 
 
 


                                         Disc_allo_MSV protocol. v.1.6 1                             47 
 
ANNEX V. Visual analog scale (lumbar and sciatic pain) 
Visual Analog Scale (VAS) 
NAME AND SURNAME: 
Date 
Measurement of back pain (low back pain) in your daily life: 
Assess your current pain while doing activities of your daily life in the last 4 weeks, 
putting a vertical mark on the horizontal line that we present to you. 
The left side represents the absence of pain and the right, excruciating pain. 
----------------------------------------------------------------- 
(No pain)                                             Maximum pain 
 
 
 
Measurement of leg pain (sciatic pain) in daily activities. 
Assess the sciatic pain that you present today when carrying out activities of your daily 
life in the last 4 weeks, putting a vertical mark on the horizontal line that we present. 
The left side represents the absence of pain and the right, a pain unbearable. 
--------------------------------------------------- 
(No pain)                              Maximum pain 
Thank you very much for your help. 
 
 
 
 
 
 


                                         Disc_allo_MSV protocol. v.1.6 1                             48 
 
 
ANNEX VI: OSWESTRY DISABILITY INDEX 
 
Name and surname:……………………………………………………………………………. 
Date:………………………………………. 
In the following activities, mark with a cross the phrase that in each question is more 
closely match your situation: 
1.Intensity of pain 
or (0) I can bear the pain without needing to take painkillers 
or (1) The pain is strong but I manage without taking painkillers 
or (2) Pain relievers completely relieve my pain 
or (3) Pain relievers give me some pain relief 
or (4) Pain relievers hardly relieve my pain 
or (5) Pain relievers do not relieve my pain and I do not take them 
2 stand up 
or (0) I can stand as long as I want without increasing pain 
or (1) I can stand as long as I want but it increases the pain 
or (2) Pain prevents me from standing for more than an hour 
or (3) Pain prevents me from standing for more than half an hour 
or (4) Pain prevents me from standing for more than 10 minutes 
or (5) Pain prevents me from standing 
3.Personal care 
or (0) I can manage on my own without increasing pain 
or (1) I can manage on my own but this increases the pain 
or (2) Washing, dressing, etc., causes me pain and I have to do it slowly and with 
watch out 
or (3) I need some help but I manage to do most of the things myself 
or (4) I need help to do most of the things 
or (5) I can't get dressed, I find it hard to wash and I usually stay in bed 
4.Sleep 
or (0) Pain does not prevent me from sleeping well 
or (1) I can only sleep if I take pills 
or (2) Even taking pills I sleep less than 6 hours 
or (3) Even taking pills I sleep less than 4 hours 
or (4) Even taking pills I sleep less than 2 hours 
or (5) Pain totally prevents me from sleeping 
5.Lift weight 
or (0) I can lift heavy objects without increasing pain 
or (1) I can lift heavy objects but it increases the pain 
or (2) Pain prevents me from lifting heavy objects off the floor, but I can do it if they are 
in a comfortable place (e.g. on a table) 
or (3) Pain prevents me from lifting heavy objects, but I can lift objects light or medium 
if they are in a comfortable place 
or (4) I can only lift very light objects 
or (5) I cannot lift or lift any object 
6.Sexual activity 
or (0) My sexual activity is normal and pain is not increasing 
or (1) My sexual activity is normal but the pain increases 
or (2) My sexual activity is almost normal but the pain increases a lot 
or (3) My sexual activity has been severely limited due to pain 
or (4) My sexual activity is almost nil because of the pain 
or (5) Pain prevents me from all kinds of sexual activity 
7.Walk 
or (0) Pain does not prevent me from walking 
or (1) Pain prevents me from walking more than one kilometer 


                                         Disc_allo_MSV protocol. v.1.6 1                             49 
 
or (2) Pain prevents me from walking more than 500 meters 
or (3) Pain prevents me from walking more than 250 meters 
or (4) I can only walk with a cane or crutches 
or (5) I stay in bed most of the time and have to crawl to the bathroom 
8.Social life 
or (0) My social life is normal and the pain does not increase 
or (1) My social life is normal but it increases the pain 
or (2) The pain does not have a significant effect on my social life, but it does prevent 
my more energetic activities like dancing, etc. 
or (3) Pain has limited my social life and I don't go out as often 
or (4) Pain has limited my social life to home 
or (5) I have no social life because of the pain 
9. Sitting 
or (0) I can sit in any type of chair for as long as I want 
or (1) I can sit in my favorite chair for as long as I want 
or (2) Pain prevents me from sitting for more than an hour 
or (3) Pain prevents me from sitting for more than half an hour 
or (4) Pain prevents me from sitting for more than 10 minutes 
or (5) Pain prevents me from sitting 
10.Travel 
or (0) I can travel anywhere without increasing pain 
or (1) I can travel anywhere, but it increases the pain 
or (2) The pain is strong but I can endure trips of more than 2 hours 
or (3) Pain limits me to trips of less than an hour 
or (4) The pain limits me to short and necessary trips of less than half an hour 
or (5) Pain prevents me from traveling except to go to the doctor or hospital 
Thank you very much for answering the questionnaire 
 
 
 
 
 


                                         Disc_allo_MSV protocol. v.1.6 1                             50 
 
ANNEX VII: SF-12 HEALTH QUESTIONNAIRE 
SF-12v.2 HEALTH QUESTIONNAIRE (Short version of SF-36) 
(Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, Bullinger M, 
Kaasa S, Leplege A, Prieto L & Sullivan M. (1998). Cross-validation of item selection 
and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA 
Project. International Quality of Life Assessment. J Clin Epidemiol 51, 1171-1178.) 
 
 
 
ANNEX VIII. MODIC CHANGES 
MODIC CHANGES. 
Described by Modic in 1988 is a common and usual observation in a projection of 
magnetic resonance imaging, are changes in signal intensity in the spinal cord bone of 
the vertebra in the area adjacent to the ends of the vertebral discs degenerative. 
They represent different histological states of the subchondral bone marrow. 
It is common to find these changes in patients with nonspecific low back pain and is 
associated with pain. However, it should be noted that these changes may be present 
in the individuals without low back pain. 
Modic I: 
Corresponds to inflammatory changes with neovascularization, which determine 
prolongation of T1 and T2 with decreased signal in T1 and hypersignal in T2. 
Histologically it is correlates with microfractures and edema in the vertebral platforms, 
in addition to tissue vascularized granulatory fibrous, such that changes can be 
demonstrated with use gadolinium. These alterations are reversible or can progress to 
stages II and III. 
Modic II: 
Corresponds to degenerative fat infiltration and bone demineralization of the bone 
spongy subchondral. Consequently, there is shortening of T1 with increased signal in 
T1-weighted sequence and T2 prolongation with increased signal in sequences 
boosted in T2. 
Modic III: 
It corresponds to the so-called "discogenic sclerosis" that is observed in plain 
radiography in vertebral platforms and is due to regeneration with bone remodeling 
subchondral, which determine T1 prolongation and T2 shortening with hyposignal in T1 
and T2 weighted sequences 
In summary, the signs of MRI are: 
 TYPE I T1 low T2 rises = edema 
 TIP0 II T1 rises T2 equal or rises = fat degeneration 
 TYPE III T1 low T2 low = bone sclerosis